

RECEIVED
CENTRAL FAX CENTER

FEB 26 2007

FAX TRANSMISSION

DATE: February 26, 2007

PTO IDENTIFIER: Application Number 10/010,942-Conf. #5594
Patent Number

Inventor: Guriq BASI et al.

MESSAGE TO: US Patent and Trademark Office

FAX NUMBER: (571) 273-8300

FROM: LAHIVE & COCKFIELD, LLP
Amy E. Mandragouras, Esq.

PHONE: (617) 227-7400

Attorney Dkt. #: ELN-002

PAGES (Including Cover Sheet): 114

CONTENTS:	Fee Transmittal (1 page) Transmittal (1 page) Petition for Reconsideration Under 37 CFR 1.705(b) and/or 1.705(c) Exhibits 1-17 Certificate of Transmission (1 page)
-----------	---

If your receipt of this transmission is in error, please notify this firm immediately by collect call to sender at (617) 227-7400 and send the original transmission to us by return mail at the address below.

This transmission is intended for the sole use of the individual and entity to whom it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution or duplication of this transmission by someone other than the intended addressee or its designated agent is strictly prohibited.

LAHIVE & COCKFIELD, LLP
One Post Office Square, Boston, Massachusetts 02109-2127
Telephone: (617) 227-7400 Facsimile: (617) 742-4214

RECEIVED
CENTRAL FAX CENTER

FEB 26 2007

PTO/SB/97 (09-04)

Approved for use through 07/31/2008 OMB 0851-0031

U S Patent and Trademark Office, U S DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application No (if known) 10/010,942

Attorney Docket No.: ELN-002

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office

on February 26, 2007
Date



Signature

Amy E. Mandragouras, Esq.

Typed or printed name of person signing Certificate

36,207 (617) 227-7400
Registration Number, if applicable Telephone Number

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper

Fee Transmittal (1 page)
Transmittal (1 page)
Petition for Reconsideration Under 37 CFR 1.705(b) and/or 1.705(c)
Exhibits 1-17

RECEIVED
CENTRAL FAX CENTER


FEB 26 2007

PTO/SB/21 (09-08)

Approved for use through 03/31/2007 OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	10/010,942-Conf #5594
	Filing Date	December 6, 2001
	First Named Inventor	Guriq BASI
	Art Unit	1649
	Examiner Name	K. A. Ballard
	Attorney Docket Number	ELN-002
Total Number of Pages in This Submission		
ENCLOSURES (Check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Petition for Reconsideration Under 37 CFR 1.705(b) and/or 1.705(c); Exhibits 1-17; Certificate of Transmission under 37 CFR 1.8
Remarks		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm Name	LAHIVE & COCKFIELD, LLP	
Signature		
Printed name	Amy E. Mandragouras, Esq	
Date	February 26, 2007	Reg No 36,207

I hereby certify that this paper (along with any paper referred to as being annexed or enclosed) is being transmitted by facsimile to the Patent and Trademark Office, facsimile no. (571) 273-8300 at Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Dated: February 26, 2007

Signature

(Amy E. Mandragouras, Esq.)

RECEIVED
CENTRAL FAX CENTER

T-957 P.04

F-797

FEB 26 2007

PTO/SB/17 (07-06)
Approved for use through 01/31/2007. OMB 0651-0032
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.

Effective on 12/08/2004
Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4618)

FEE TRANSMITTAL

For FY 2006

☐ Applicant claims small entity status See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT		(\$)		0.00	
--------------------------------	--	------	--	------	--

Complete if Known

Application Number	10/010,942-Conf. #5594
Filing Date	December 6, 2001
First Named Inventor	Gung BASI
Examiner Name	K. A. Ballard
Art Unit	1649
Attorney Docket No	ELN-002

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify): _____

☒ Deposit Account Deposit Account Number 12-0080 Deposit Account Name Lahive & Cockfield, LLP

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☐ Charge fee(s) indicated below, except for the filing fee

☒ Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17 ☒ Credit any overpayments

FEE CALCULATION

1. BASIC FILING, SEARCH, AND EXAMINATION FEES

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

2. EXCESS CLAIM FEES

Fee Description	Fee (\$)	Small Entity Fee (\$)
Each claim over 20 (including Reissues)	50	25
Each independent claim over 3 (including Reissues)	200	100
Multiple dependent claims	360	180

Multiple Dependent Claims

Total Claims	Extra Claims	Fee (\$)	Fee Paid (\$)
_____ - 20 = _____	x _____	= _____	

HP = highest number of total claims paid for, if greater than 20.

Indep. Claims	Extra Claims	Fee (\$)	Fee Paid (\$)
_____ - 3 = _____	x _____	= _____	

HP = highest number of independent claims paid for, if greater than 3.

3. APPLICATION SIZE FEE


If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(c)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof	Fee (\$)	Fee Paid (\$)
_____ - 100 = _____	/50	(round up to a whole number) x _____	= _____	

4. OTHER FEE(S)


Non-English Specification. \$130 fee (no small entity discount)	400.00
Other (e.g., late filing surcharge). Petition for Reconsideration Under 37 CFR 1.705(b)	200.00
Petition for Reconsideration Under 37 CFR 1.705(c)	

SUBMITTED BY

Signature 	Registration No. (Attorney/Agent) <u>36,207</u>	Telephone <u>(617) 227-7400</u>
Name (Print/Type) <u>Amy E. Mandragouras, Esq.</u>	Date <u>February 26, 2007</u>	

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted by facsimile to the Patent and Trademark Office, facsimile no. (571) 273-8300 at Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: February 26, 2007

Signature  (Amy E. Mandragouras, Esq.)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted by facsimile to the Patent and Trademark Office, Office of Petitions, facsimile no (571) 273-8700 at Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Dated February 26, 2007

Signature
(Amy A. Mandragoras)

Docket No.: ELN-002
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Guriq Basi *et al.*

RECEIVED
CENTRAL FAX CENTER

FEB 26 2007

Application No.: 10/010942

Confirmation No.: 5594

Filed: December 6, 2001

Art Unit: 1649

For: HUMANIZED ANTIBODIES THAT
RECOGNIZE BETA AMYLOID PEPTIDE

Examiner: Ballard, Kimberly A.

MS Petition
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**REQUEST FOR RECONSIDERATION OF AN APPLICATION FOR
PATENT TERM ADJUSTMENT PURSUANT TO 37 C.F.R. §1.705(b) AND/OR §1.705(c)**

Dear Sir:

Pursuant to 37 C.F.R. §1.705(b) and/or §1.705(c), Applicants hereby petition for reconsideration of the Application for Patent Term Adjustment filed on August 10, 2006 (hereinafter, "the Application") for the above-referenced patent application. This petition is timely filed within two months of the date of Decision on Application for Patent Term Adjustment dated December 26, 2006 (hereinafter "the Decision"). A copy of the Decision and the Application are filed with this petition as Exhibits 1 and 2.

In the Decision the Petitions Examiner denied Applicants' request for correction of the period of reduction of 107 days for Applicant delay under 37 C.F.R. § 1.704(b) and entry of a new period of Applicant delay of 38 days in connection with Applicants' response to the Notice to File Missing Parts mailed March 1, 2002 (See Decision on Petition, page 1, paragraph 4 to page 2, paragraph 4). The Examiner's denial of the request was on the grounds that Applicants' response to the Notice to File Missing Parts filed by Certificate of Mailing on July 1, 2002 (and date stamped on July 8, 2002) allegedly contained an omission and that the period of 69 days

Serial No. 10/010,942

ELN-002

(beginning July 9, 2002 and ending September 16, 2002 with the filing of a paper correcting the omission) constituted a "failure to engage" pursuant to 37 C.F.R. § 1.704(c)(7).

As indicated by the Notice to Comply with Requirements for Patent Application Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" mailed August 21, 2002, the alleged omission in this case is that Applicants' response of July 1, 2002 was missing a compliant sequence disk. The Notice indicates that the computer diskette was found to be "damaged and/or unreadable." (see Exhibit 3)

Applicants respectfully request reconsideration of the Application for Patent Term Adjustment on the grounds that Applicants' response did not in fact contain an "omission" on the part of the Applicants and, further, that the period of 69 days is not a "failure to engage" by Applicants. In particular, Applicants respectfully submit that Applicants filed a fully compliant response, including a fully compliant sequence disk on July 1, 2002. The fact that the disk was subsequently found to be damaged by the USPTO was not due to any lack of due care by Applicants, but instead due to the subsequent handling and treatment of the disk by others. Based on information provided by personnel at the USPTO following inspection of the USPTO file copy of the sequence disk filed on July 1, 2002, it is Applicants' understanding that the sequence disk is visibly damaged in a manner consistent with damage caused by irradiation treatment of the disk by the United States Postal Service. As such, Applicants' reply did not have an omission and the period of adjustment set forth in §1.703 should not have been reduced by 69 days (the number of days beginning on the day after the date of the reply having the alleged omission (i.e., July 9, 2002) and ending on the date a reply correcting the omission was filed (i.e., September 16, 2002)). Evidence in support of Applicants request for reconsideration is set forth below:

- I. Applicants' reply did not contain an omission as the sequence diskette of July 1, 2002 was fully compliant.

In support of their request for reconsideration, Applicants submit herewith copies of the following documents as evidence that Applicants' reply of July 1, 2002 did not contain an

Serial No. 10/010,942

ELN-002

omission and that the sequence disk was compliant and any damage was due to the subsequent handling and treatment by others:

- (1) A true copy of the return postcard dated July 1, 2002, originally filed with the above-referenced sequence disk describing the papers that constituted the filing package and indicating that a "Diskette containing the computer readable form of the Sequence Listing" was enclosed with a Certificate of First Class Mailing and indicating USPTO date-stamp of July 8, 2002 (see Exhibit 4; 1 page);
- (2) A true copy of Applicants' Attorney's file copy of the diskette label affixed to an envelope containing the sequence disk mailed July 1, 2002 and indicating that the sequence disk is dated July 1, 2002 (Exhibit 5);
- (3) A true paper copy of a sequence listing generated from Applicants' Attorney's file copy the sequence diskette mailed on July 1, 2002 (Exhibit 6);
- (4) A Verification Summary Report generated by the USPTO's "Checker" software program confirming that there are no sequence errors in Applicants' Attorney's file copy of the July 1, 2002 sequence listing (Exhibit 7);
- (5) An Affidavit executed by Ms. Micaela Hill affirming that Applicants' Attorney's file copy of the sequence diskette mailed July 1, 2002 is computer-readable and that the paper copy submitted as Exhibit 6 was generated from Applicants' Attorney's file copy of said sequence diskette (Exhibit 8);
- (6) A true paper copy of a sequence listing generated from Assignees' file copy of the sequence diskette mailed on July 1, 2002 (Exhibit 9);
- (7) An Affidavit executed by Ms. Patricia Robinson affirming that Assignees' file copy of the sequence diskette mailed July 1, 2002 is computer-readable and that the paper copy submitted as Exhibit 9 was generated from Assignees' file copy of said sequence diskette (Exhibit 10);
- (8) An Affidavit executed by Debra J. Milasincic, Esq. describing Applicants' Attorney's regular practice in connection with the preparation of sequence listings and sequence diskettes (Exhibit 11);

Serial No. 10/010,942

ELN-002

(9) A true copy of the return postcard dated September 16, 2002, filed in response to the Notice to Comply and describing the papers that constituted the filing package and indicating that a "Diskette containing the computer readable form of the Sequence Listing" was enclosed with a Certificate of First Class Mailing and indicating USPTO date-stamp of September 20, 2002 (see Exhibit 12);

(10) A true copy of Applicants' Attorney's copy of the sequence diskette and envelope filed September 16, 2002 and indicating that the sequence disk is dated September 16, 2002 (Exhibit 13);

(11) A true paper copy of Applicants' sequence listing filed September 19, 2002 which was found to be compliant (Exhibit 14);

(12) A Statement from Applicants' Attorney confirming that Applicants' Attorney's paper copy of sequence listing filed July 1, 2002 (Exhibit 6) is identical to Applicants' Attorney's paper of the sequence listing filed September 19, 2002 (Exhibit 15).

Therefore, the fact that the sequence disks mailed July 1, 2002 and September 19, 2002 are identical and that the September 19, 2002 diskette was found to be compliant, is evidence that Applicants' diskette mailed July 1, 2002 was also compliant and that Applicants' Attorney used due care. Accordingly, Applicants respectfully submit that Applicants' reply of July 1, 2002 did not contain an omission in that the sequence disk mailed July 1, 2002 was fully compliant, but subsequently damaged by the handling and treatment of others.

II. The sequence disk filed July 1, 2002 was damaged by the handling and treatment by the United States Postal Service.

Evidence in support of Applicants' assertion that the sequence disk of July 1, 2002 was subsequently damaged by treatment of the disk by others following deposit by Applicants can be found by inspection of the USPTO's file copy of the sequence disk filed July 1, 2002. At Applicants' request, Mr. Christopher Lowe, USPTO Quality Assurance Specialist for Technology Center 1600 conducted a visual inspection of the file. Following visual inspection of the sequence disk mailed July 1, 2002, Mr. Lowe indicated to Applicants' Attorneys that the

Serial No. 10/010,942

ELN-002

disk was "warped" and had "a quarter inch bow in it." It is Applicants' Attorney's understanding that this type of damage is consistent with the irradiation of mail by the United States Postal Service in response to the threat of anthrax poisoning in the Washington D.C. area during the months following the September 11, 2001 terrorist attacks. Sequence disks and other mail submitted to the USPTO in late 2001- mid 2002 were often "damaged" as a result of anthrax irradiation procedures conducted in Lima, Ohio for all mail mailed to the Washington D.C. zip code (20231) of the USPTO (see OG Notice dated January 15, 2002 (Exhibit 16) and Letter dated January 16, 2002 from Commissioner Nicholas P. Godici (Exhibit 17)). Indeed, Applicants' sequence disk was mailed to the 20231 zip code.

As indicated in the OG Notice of January 15, 2002 (Exhibit 16), the USPTO has previously considered mail delays necessitated by the anthrax decontamination process and their effect on Patent Term Adjustment (see Pages 6-8 of Exhibit 16). Where a reply to an Office Action or Notice was mailed on or after October 13, 2001 and no later than December 1, 2001, and where an applicant subsequently received a reduction in Patent Term Adjustment pursuant to 37 C.F.R. §1.704(b) for a delayed receipt of the reply by the USPTO, the USPTO later recognized the mailing date of the reply as a "sufficient showing" that, in spite of all due care, the applicant was unable to reply to the Office Action or Notice within three months of the date of mailing. In these situations, the USPTO saw fit to reinstate applicant's Patent Term Adjustment for any period of delay that exceeded three business days.

Applicants submit that a set of circumstances has occurred in the instant case which are similar to those set forth in Exhibit 16. Here, the evidence indicates that Applicant filed a compliant response including a compliant sequence disk, but that the sequence disk was later damaged by the treatment of others. Given these circumstances, Applicants respectfully submit that they should not be penalized for the 69 day period during which the USPTO mailed a Notice to Comply and Applicants filed a second compliant sequence disk. Applicants submit that they engaged in reasonable efforts to conclude processing of the application by filing a compliant sequence disk on July 1, 2002 which was later rendered defective by circumstances beyond their control. In the alternative, Applicants request reconsideration of the Application for Patent Term Adjustment for either of the following: (i) reinstatement of the 69 day period of adjustment pursuant to 37 C.F.R. §1.705(c) on the grounds that the evidence submitted herewith provides a sufficient showing that, in spite of all due care, the Applicant was unable to respond

Serial No. 10/010,942

ELN-002

to the Notice to File Missing Parts on July 1, 2002 due to unforeseeable circumstances; or (ii) suspension or waiver of 37 C.F.R. § 1.704(c)(7) with respect to the 69 day period in view of these circumstances in accordance with 37 C.F.R. §1.183. In any event, Applicants request correction of the period of reduction of 107 days and entry of a new delay period of 38 days as originally requested.

It is Applicants' Attorney's understanding that the filing of the instant Petition is also not a "failure to engage" by Applicants. This understanding is based on a discussion between Applicants' Agent and the Petitions Examiner in which the Examiner informed Applicants' Agent that the issue of whether or not the sequence disk filed July 1, 2002 was compliant is a valid petitionable issue and not a "frivolous" one. It is Applicant's Attorneys' further understanding that the instant petition is effectively part of the original Application for Patent Term Adjustment and is therefore subject to the "safe harbour" provisions of 37 C.F.R. § 1.704(e). Nevertheless, should the USPTO attribute any period of Applicant Delay due to the filing of the instant petition, it is Applicants' understanding that a Certificate of Correction will be issued by the Petitions Examiner to remove this period as Applicant Delay.

Please charge the appropriate fees set forth in 37 C.F.R. §1.705(b) and 37 C.F.R. §1.705(c) to Account No.: 12-0080. However, if any additional fees are determined to be due, the Commissioner is authorized to withdraw such fees from Account No.: 12-0080.

Dated: February 26, 2007

Respectfully submitted,

By

Amy E. Mandragouras
Registration No.: 36,207
LAHIVE & COCKFIELD, LLP
28 State Street
Boston, Massachusetts 02109
(617) 227-7400
(617) 742-4214 (Fax)
Attorney/Agent For Applicant



UNITED STATES PATENT AND TRADEMARK OFFICE

EXHIBIT 1

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
P.O. BOX 1480
ALEXANDRIA, VA 22313-1480
www.uspto.gov

Paper No.

LAHIVE & COCKFIELD, LLP
ONE POST OFFICE SQUARE
BOSTON MA 02109-2127

COPY MAILED

DEC 26 2006

OFFICE OF PETITIONS

In re Application of :
Basi et al. : DECISION ON APPLICATION
Application No. 10/010,942 : FOR
Filed: December 6, 2001 : PATENT TERM ADJUSTMENT
Attorney Docket No. ELN-002 :

This is a decision on the "APPLICATION FOR PATENT TERM ADJUSTMENT INCLUDING REQUEST FOR RECONSIDERATION UNDER 37 CFR §1.705(b)," filed August 10, 2006. Applicants request that the determination of patent term adjustment be corrected from zero (0) days to at least five hundred eight (508) days.

The application for patent term adjustment is GRANTED to the extent indicated herein.

The Office has updated the PAIR screen to reflect that the correct Patent Term Adjustment (PTA) determination at the time of the mailing of the Notice of Allowance is ZERO (0) days, including an additional period of reduction of 12 days for applicant delay. A copy of the updated PAIR screen, showing the correct determination, is enclosed.

On May 11, 2006, the Office mailed the Determination of Patent Term Adjustment under 35 U.S.C. 154(b) in the above-identified application. The Notice stated that the patent term adjustment (PTA) to date is 0 days. The instant application for patent term adjustment was timely filed¹. Applicants dispute the reduction of 107 days associated with their filing of a response on September 16, 2002 to the Notice to File Missing Parts of

¹ PALM records indicate that the Issue Fee was received on August 11, 2006.

Application No. 10/010,942

Page 2

Application mailed March 1, 2002. Applicants contend that their response was filed on July 9, 2002, and thus, the period of reduction pursuant to 1.704(b) is 38 days.

Applicants disclose that a period of reduction of 12 days should be entered for their filing of an Information Disclosure Statement on March 12, 2006. This period has been entered.

37 C.F.R. §1.704(c)(7) provides that a period of reduction is entered for:

Submission of a reply having an omission (§1.135(c)), in which case the period of adjustment set forth in § 1.703 shall be reduced by the number of days, if any, beginning on the day after the date the reply having an omission was filed and ending on the date that the reply or other paper correcting the omission was filed.

In this instance, a response was filed on July 9, 2002, three months and 38 days after the mailing of the Notice. Further, this response as indicated by the Notice to Comply mailed August 21, 2002, had an omission. On September 16, 2002, 69 days later, applicant filed the paper correcting the omission. Accordingly, pursuant to 37 CFR §§ 1.704(b) and 1.704(c)(7), a total period of 107 days was entered for applicant delay associated with these two failures to engage.

In view thereof, the correct determination of patent term adjustment at the time of the mailing of the notice of allowance is ZERO (0) days.


Receipt of the \$200.00 fee set forth in 37 CFR 1.18(e) is acknowledged. No additional fees are required.

The Office of Patent Publication has been advised of this decision. The application is thereby forwarded to the Office of Patent Publication for issuance of the patent. The patent term adjustment indicated on the patent (as shown on the Issue Notification mailed about three weeks prior to patent issuance) will include any additional adjustment accrued both for Office delay in issuing the patent more than four months after payment of the issue fee and satisfaction of all outstanding requirements, and for the Office taking in excess of three years to issue the patent (to the extent that the three-year period does not overlap with periods already accorded).

Application No. 10/010,942

Page 3

Telephone inquiries specific to this matter should be directed to the undersigned at (571) 272-3219.

A handwritten signature in black ink, appearing to read "Nancy Johnson". The signature is fluid and cursive, with the first name "Nancy" written in a larger, more prominent script than the last name "Johnson".

Nancy Johnson
Senior Petitions Attorney
Office of Petitions

Enclosure: Copy of Revised PAIR Screen

Day : Thursday
Date: 12/21/2006

Time: 07:33:59

PALM INTRANET

PTA Calculations for Application: 10/010942					
Application Filing Date:		12/06/2001	PTO Delay (PTO):		244
Issue Date of Patent:			Three Years:		0
Pre-Issue Petitions:		0	Applicant Delay (APPL):		392
Post-Issue Petitions:		0	Total PTA (days):		0
PTO Delay Adjustment:		-12			

File Contents History					
Number	Date	Contents Description	PTO	APPL	START
110	12/21/2006	ADJUSTMENT OF PTA CALCULATION BY PTO		69	
109	12/21/2006	ADJUSTMENT OF PTA CALCULATION BY PTO		38	
108	12/21/2006	ADJUSTMENT OF PTA CALCULATION BY PTO	73		
107	12/21/2006	ADJUSTMENT OF PTA CALCULATION BY PTO	107		
106	12/21/2006	ADJUSTMENT OF PTA CALCULATION BY PTO		73	
105	12/21/2006	ADJUSTMENT OF PTA CALCULATION BY PTO		12	
85	05/11/2006	MAIL NOTICE OF ALLOWANCE			
84	05/11/2006	MAIL FORMAL DRAWINGS REQUIRED			
83	05/11/2006	MAIL EXAMINER INTERVIEW SUMMARY (PTOL - 413)			
82	05/10/2006	ISSUE REVISION COMPLETED			
81	05/10/2006	FORMAL DRAWINGS REQUIRED			
80	05/10/2006	NOTICE OF ALLOWANCE DATA VERIFICATION COMPLETED			
79	05/10/2006	CASE DOCKETED TO EXAMINER IN GAU			
78	05/10/2006	NOTICE OF ALLOWABILITY			
77	04/24/2006	EXAMINER INTERVIEW SUMMARY RECORD (PTOL - 413)			
76	05/01/2006	MAIL EXAMINER INTERVIEW SUMMARY (PTOL - 413)			
75	04/11/2006	EXAMINER INTERVIEW SUMMARY RECORD (PTOL - 413)			
74	03/15/2006	INFORMATION DISCLOSURE STATEMENT CONSIDERED			
73	03/03/2006	INFORMATION DISCLOSURE STATEMENT CONSIDERED			
72	12/22/2005	INFORMATION DISCLOSURE STATEMENT CONSIDERED			

71	03/15/2006	REFERENCE CAPTURE ON IDS			
70	03/15/2006	INFORMATION DISCLOSURE STATEMENT (IDS) FILED			
69	03/03/2006	NEW OR ADDITIONAL DRAWING FILED			
68	03/13/2006	DATE FORWARDED TO EXAMINER			
67	03/03/2006	RESPONSE AFTER NON-FINAL ACTION		59	59
66	03/03/2006	REQUEST FOR EXTENSION OF TIME - GRANTED			
65	03/03/2006	REFERENCE CAPTURE ON IDS			
64	03/03/2006	INFORMATION DISCLOSURE STATEMENT (IDS) FILED			
63	02/22/2006	MAIL EXAMINER INTERVIEW SUMMARY (PTOL - 413)			
62	02/16/2006	EXAMINER INTERVIEW SUMMARY RECORD (PTOL - 413)			
61	12/22/2005	REFERENCE CAPTURE ON IDS			
60	12/22/2005	INFORMATION DISCLOSURE STATEMENT (IDS) FILED			
59	10/03/2005	MAIL NON-FINAL REJECTION	14		47
58	09/29/2005	NON-FINAL REJECTION			
57	08/24/2005	CASE DOCKETED TO EXAMINER IN GAU			
56	06/28/2005	CASE DOCKETED TO EXAMINER IN GAU			
55	05/24/2005	INFORMATION DISCLOSURE STATEMENT (IDS) FILED		5	47
54	06/02/2005	IFW TSS PROCESSING BY TECH CENTER COMPLETE			
53	06/02/2005	CASE DOCKETED TO EXAMINER IN GAU			
52	11/29/2004	REFERENCE CAPTURE ON IDS			
51	11/29/2004	INFORMATION DISCLOSURE STATEMENT (IDS) FILED			
50	05/24/2005	REFERENCE CAPTURE ON IDS			
48	06/01/2005	DATE FORWARDED TO EXAMINER			
47	05/19/2005	RESPONSE AFTER NON-FINAL ACTION		30	44
46	05/19/2005	REQUEST FOR EXTENSION OF TIME - GRANTED			
45	05/25/2005	CASE DOCKETED TO EXAMINER IN GAU			
44	01/19/2005	MAIL NON-FINAL REJECTION			
43	01/19/2005	NON-FINAL REJECTION			
42	12/16/2004	INFORMATION DISCLOSURE STATEMENT (IDS) FILED		20	38

41	12/20/2004	DATE FORWARDED TO EXAMINER			
40	12/14/2004	SUPPLEMENTAL RESPONSE			
39	12/07/2004	DATE FORWARDED TO EXAMINER			
38	11/26/2004	RESPONSE AFTER NON-FINAL ACTION		92	35
37	11/26/2004	REQUEST FOR EXTENSION OF TIME - GRANTED			
36	11/26/2004	WORKFLOW INCOMING AMENDMENT IFW			
35	05/26/2004	MAIL NON-FINAL REJECTION			
34	05/25/2004	NON-FINAL REJECTION			
33	03/18/2004	DATE FORWARDED TO EXAMINER			
32	03/12/2004	RESPONSE TO ELECTION / RESTRICTION FILED		79	26
29	03/12/2004	REQUEST FOR EXTENSION OF TIME - GRANTED			
28	12/19/2003	CORRESPONDENCE ADDRESS CHANGE			
27	09/20/2003	PRELIMINARY AMENDMENT			
26	09/24/2003	MAIL RESTRICTION REQUIREMENT	230		-1
25	09/24/2003	REQUIREMENT FOR RESTRICTION / ELECTION			
24	09/17/2003	CASE DOCKETED TO EXAMINER IN GAU			
23	10/03/2002	INFORMATION DISCLOSURE STATEMENT (IDS) FILED			
22	07/09/2002	PRELIMINARY AMENDMENT			
21	05/27/2003	CASE DOCKETED TO EXAMINER IN GAU			
20	04/21/2003	CASE DOCKETED TO EXAMINER IN GAU			
19	10/11/2002	APPLICATION DISPATCHED FROM OIPE			
18	10/10/2002	APPLICATION IS NOW COMPLETE			
17	09/16/2002	ADDITIONAL APPLICATION FILING FEES		107	8
16	09/16/2002	CRF DISK HAS BEEN RECEIVED BY PREEXAM / GROUP / PCT			
15	10/07/2002	CRF IS GOOD TECHNICALLY / ENTERED INTO DATABASE			
14	08/25/2002	RECEIPT OF ALL ACKNOWLEDGEMENT LETTERS			
13	08/21/2002	SEQUENCE ERRORS			
12	07/01/2002	PAYMENT OF ADDITIONAL FILING FEE/PREEXAM			
11	07/01/2002	CRF DISK HAS BEEN RECEIVED BY PREEXAM / GROUP / PCT			
10	07/01/2002	A STATEMENT BY ONE OR MORE INVENTORS SATISFYING THE REQUIREMENT UNDER 35 USC 115, OATH OF THE APPLIC			

9	07/30/2002	CRF DOES NOT MATCH APPLICATION SPECIFICATION -- APPLICANT MUST CORRECT			
8	03/01/2002	NOTICE MAILED--APPLICATION INCOMPLETE--FILING DATE ASSIGNED			
6	01/15/2002	REFERRED BY L&R FOR THIRD-LEVEL SECURITY REVIEW. AGENCY REFERRAL LETTER GENERATED			
5	01/10/2002	IFW SCAN & PACR AUTO SECURITY REVIEW			
4	01/04/2002	CRF IS FLAWED TECHNICALLY / NOT ENTERED INTO DATABASE			
3	12/19/2001	IFW SCAN & PACR AUTO SECURITY REVIEW			
2	12/06/2001	CRF DISK HAS BEEN RECEIVED BY PREEXAM / GROUP / PCT			
1	12/06/2001	INITIAL EXAM TEAM NN			

Search Another: Application#

EXPLANATION OF PTA CALCULATION**EXPLANATION OF PTE CALCULATION**

To go back use Back button on your browser toolbar

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

EXHIBIT 2

EXPRESS MAIL LABEL NO.: EV 465008962US August 10, 2006

Docket No.: ELN-002
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Guriq Basi *et al.*

Application No.: 10/010942

Confirmation No.: 5594

Filed: December 6, 2001

Art Unit: 1649

For: HUMANIZED ANTIBODIES THAT
RECOGNIZE BETA AMYLOID PEPTIDE

Examiner: Ballard, Kimberly A.

MS Petition
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT UNDER 37 CFR § 1.702(b)(2)

Dear Sir:

1. This statement is respectfully submitted in support of the "Application for Patent Term Adjustment Including Request for Reconsideration Under 37 CFR §1.705(b)" for the above-referenced application. In view of the following, it is respectfully requested that Applicants be granted a minimum patent term adjustment of 508 days, with an additional term to be added based on the number of days following payment of the issue fee on August 11, 2006 to the date of issuance of a patent for the above-referenced application.

2. The patent term adjustment on the Determination of Patent Term Adjustment Under 35 U.S.C. §154(b) ("PTAS Sheet") that was attached to the Notice of Allowance is 0 days (a copy of the PTAS Sheet is submitted herewith as Exhibit A). This determination of 0 days is in error in that pursuant to 35 U.S.C. §154(b) the Office failed to take certain action within the time frame specified in 37 CFR §1.702(a) and failed to issue a patent within three years of the actual filing date of the above-referenced application in accordance with 37 CFR §1.702(b).

USSN 10/010,942

Group Art Unit: 1649

Pursuant to 37 CFR §1.703(a), Applicants are entitled to a period of patent term adjustment due to the failure by the Office to mail an action under 35 U.S.C. §132 not later than 14 months after the actual filing date (*i.e.*, by February 6, 2003) (hereinafter "14 Month Delay"). As the Office failed to mail an action under 35 U.S.C. §132 until September 24, 2003, Applicants are entitled to a period of patent term adjustment beginning on the day after the date that is 14 months after the date on which the above-referenced application was filed under 35 U.S.C. §111(a), *i.e.*, February 7, 2003, and ending on the date of mailing of an action under 35 U.S.C. §132, *i.e.*, September 24, 2003. Accordingly, the period of patent term adjustment due to the 14 Month Delay by the Office is 230 days, which is in agreement with the period calculated by the Office on the PTAS Sheet (Exhibit A, line 25).

In addition to the patent term adjustment due to the 14 Month Delay, pursuant to 37 CFR §1.703(b) Applicants are entitled to a period of patent term adjustment due to examination delay from the number of days in the period beginning on the day after the date that is three years after the date on which the above-referenced application was filed under 35 U.S.C. §111(a), *i.e.*, December 7, 2004, and ending on the date a patent is issued, (hereinafter "Three Years Delay"). As the issue date has yet to be determined, Applicants have calculated a minimum period of Three Years Delay of 613 days, based on a hypothetical issue date of August 11, 2006, the projected date of payment of the issue fee.

As set forth in 37 CFR §1.703(f), Applicants are entitled to a period of patent term adjustment equal to the period of examination delays based on the grounds set forth in 37 CFR §1.702 reduced by the period of time equal to the period of time during which Applicants failed to engage in reasonable efforts to conclude prosecution pursuant to 37 CFR §1.704 (hereinafter "Applicant Delay"). With respect to the above-referenced application, the total period of examination delays is the sum of the period of 14 Month Delay (230 days) and the minimum period of Three Years Delay (613 days), or 843 days, to the extent these periods of delay are not overlapping. As the period of 14 Month Delay ended on November 24, 2003, prior to the first day of the period of Three Years Delay, *i.e.*, December 7, 2004, Applicants submit that these periods are not overlapping. To calculate the period of patent term adjustment, the total period

USSN 10/010,942

Group Art Unit: 1649

of examination delay is reduced by the period of Applicant Delay, which Applicants have calculated herein as a period of 335 days (not 392 days as set forth in the PTAS Sheet (Exhibit A)).

Accordingly, Applicants submit that the correct patent term adjustment for the above-referenced application is at least 508 days, which is the difference between the total period of examination delay (843 days) and the period of Applicant Delay (335 days). Applicants further submit that the term of 508 days should be extended by an additional term equal to the number of days following payment of the issue fee on August 11, 2006 to the date of issuance of a patent for the above-referenced application in accordance with 37 CFR §1.703(b). As such, the correct patent term adjustment upon issuance of a patent is expected to be the sum of 508 days (as calculated herein) and the number of days from August 12, 2006 to issuance of a patent.

3. The factual bases for the above adjustment are set forth as follows:

A Examination Delays Pursuant to 37 CFR §1.702 and §1.703

Pursuant to 37 CFR §1.703(f), the period of adjustment of the term of the patent under §1.702 is the sum of the periods of examination delay calculated under subparagraphs (a)-(e), to the extent that such periods are not overlapping, less the sum of the periods calculated under §1.704 (the period of Applicant Delay). In the above-referenced application, Applicants are entitled to a period of examination delay equal to the sum of the periods of delay under §1.703(a) and (b) for the reasons set forth below.

(i) "14 Month Delay" Pursuant to §1.703(a)(1)

In accordance 37 CFR §1.703(a)(1), Applicants are entitled to a period of patent term adjustment due to the failure by the Office to mail an action under 35 U.S.C. §132 not later than 14 months after the actual filing date (i.e., by February 6, 2003). As shown in the PTAS Sheet (Exhibit A, line 25), the Office failed to mail an action under 35 U.S.C. §132 (a Restriction

USSN 10/010,942

Group Art Unit: 1649

Requirement) until September 24, 2003. As such, Applicants are entitled to a period of patent term adjustment beginning February 7, 2003 and ending on September 24, 2003, the date of mailing of the Restriction Requirement by the Office. Accordingly, the period of patent term adjustment due to the 14 Month Delay by the Office is 230 days, as shown on line 25 of the PTAS Sheet (Exhibit A, line 25).

(ii) "Three Years Delay" Pursuant to 37 CFR §1.703(b)

It is anticipated that the Office will not comply with the requirement of 35 U.S.C. §154(b) and 37 CFR §1.702(b), which requires issuance of a patent within 3 years after the date on which the application was filed under 35 U.S.C. §111(a). As indicated in the Notice of Allowance, a patent is projected to issue on November 28, 2006, but may issue earlier or later depending on the circumstances of publication. However, even assuming *arguendo* that a patent is issued on the same day as the projected date of payment of the issue fee (*i.e.*, August 11, 2006), said issue date would be 3 years and 613 days after the date on which the above-referenced application was filed under 35 U.S.C. §111(a). As none of the exclusionary periods set forth in 37 CFR §1.702(b) apply to the instant application and in accordance with 37 CFR §1.703, a minimum period of examination delay is calculated to be at least 613 days, based on the hypothetical issue date of August 11, 2006. This minimum period of examination delay is to be extended by an additional term equal to the number of days following payment of the issue fee on August 11, 2006 to the date of issuance of a patent. Accordingly, the entire period of Three Years Delay is the sum of the minimum period of examination delay of 613 days and the number of days from August 12, 2006 to the day of issuance of the patent.

(iii) Total Examination Delay Pursuant to 37 CFR §1.703(f)

As set forth in 37 CFR §1.703(f), the period of examination delay based on the grounds set forth in 37 CFR §1.702 is the sum of the period of 14 Month Delay (230 days) and the minimum period of Three Years Delay (613 days), or 843 days, to the extent these periods of delay are not overlapping. As the period of 14 Month Delay ended on November 24, 2003, prior to the first day of the period of Three Years Delay, *i.e.*, December 7, 2004, Applicants submit that these periods are not overlapping.

USSN 10/010,942

Group Art Unit: 1649

B. "Applicant Delay" Pursuant to 37 CFR §1.704

Pursuant to 37 CFR §1.704 the period of adjustment of the term of the patent due to examination delay is reduced by the period of Applicant Delay. As indicated on the PTAS Sheet (Exhibit A), the Office has calculated a period of Applicant Delay of 392 days. Applicants respectfully submit that the correct period of Applicant Delay is 335 days and seek correction based on the following remarks. A PTAS Sheet showing corrections by Applicants is submitted herewith as Exhibit C. A copy of the "Image File Wrapper Record" and "Transaction History" from Applicants' Private PAIR are submitted herewith as Exhibits B and F.

(i) Applicant Delay for Responding to a Notice to File Missing Parts of March 1, 2002

Applicants request correction of the initial period of Applicant Delay of 107 days (line 16 of Exhibit A) from the date of mailing of a Notice to File Missing Parts of the Application on March 1, 2002 (line 7 of Exhibit A) to September 16, 2002 (line 16 of Exhibit A), the date on which Applicants are alleged to have responded. Applicants submit that the correct period of Applicant Delay is 38 days, which is the number of days in excess of 3 months from the date of the Notice to File Missing Parts (*i.e.*, June 1, 2002) to the date on which a complete response was filed by the Applicants (*i.e.*, July 9, 2002). As evidenced by the enclosed copy of a postcard receipt (submitted herewith as Exhibit D), Applicants filed a complete response to the Notice to File Missing Parts, including a computer-readable sequence disk, via first class mail on July 1, 2002. The date-in stamp on the postcard receipt indicates that these documents and sequence disk were received by the Office on July 9, 2002. Copies of the Notice to File Missing Parts from March 1, 2002 as well as Applicants' response thereto from the Image File Wrapper Record are submitted herewith as Exhibit E. Additional evidence of receipt of Applicants' complete response on July 9, 2002 is shown on the Image File Wrapper Record (Exhibit B) from this date indicating "Applicant Response to Pre-Exam Formalities Notice", "Oath or Declaration Filed" and "CFR Sequence Listing Filed," among other entries. According to 37 CFR §1.704 (b), the period of Applicant Delay begins on the day that is 3 months after the date of the Notice to Comply (*i.e.*, June 2, 2002) and ends on the date the reply was filed by Applicants (*i.e.*, July 9, 2002) for a total of 38 days. For the reasons set forth in subsection B (ii) below, Applicants

USSN 10/010,942

Group Art Unit: 1649

submit that no other Applicant Delays accrued during the period from March 1, 2002 to September 16, 2002. As such, Applicants request correction of the initial period of Applicant Delay of 107 days (line 16 of Exhibit A) to 38 days (line 12 of Exhibit C).

(ii) Applicant Delay for Responding to a Notice to Comply with Sequence Listing of August 21, 2002

Applicants respectfully submit that the Office has improperly calculated the period beginning August 22, 2002 (the day following the mail date of a "Preexam Formalities Notice" by the Office on August 21, 2002 (line 12 of Exhibit A)) and ending September 16, 2002 (the date of a response to the Preexam Formalities Notice by Applicants (line 16 of Exhibit A) as an Applicant Delay. This alleged period of delay corresponds to the period for response by Applicants to a "Preexam Formalities Notice," a "Notice to Comply with Requirement for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" ("Notice to Comply with Sequence Listing") mailed August 21, 2002 (a copy of this Notice and Applicants response is submitted herewith as Exhibit G). As shown in Exhibit G, Applicants filed a response to the Notice to Comply with Sequence Listing via first class mail on September 16, 2002. The date-in stamp by the Office indicates that the response was received on September 20, 2002. Further evidence of receipt of Applicants' complete response on September 20, 2002 is shown on the Image File Wrapper Record (Exhibit B) from this date indicating "Response to Pre-Exam Sequence Notice" and "Sequence Listing," among other entries. Pursuant to 37 CFR §1.704(b), the period of Applicant Delay begins on the day that is 3 months after the date of the Notice to Comply with Sequence Listing (*i.e.*, November 22, 2002) and ends on the date the reply was filed by Applicants. As Applicants filed a complete response to the Notice to Comply with Sequence Listing on September 20, 2002, within the three month grace period provided by 37 CFR §1.704(b), no Applicant Delay accrued.

Finally, it is respectfully submitted that the period of time from July 9, 2002 (the date of response by Applicants to the Notice to File Missing Parts) to August 21, 2002 (the date of mailing of the Notice to Comply with Sequence Listing by the Office) has been improperly calculated by the Office as a period of Applicant Delay. The alleged period of delay, a total of

USSN 10/010,942

Group Art Unit: 1649

43 days, corresponds to the time taken by the Office of Initial Patent Examination (OIPE) to process the response filed by Applicants on July 9, 2002. Applicants submit that the 43 day period is an examination delay by the Office and is not a delay by the Applicants pursuant to 37 CFR §1.704.

In view of the preceding remarks, Applicants submit that no Applicant Delays accrued during the period from July 9, 2002 to September 20, 2002. Accordingly, Applicants request correction of the initial period of Applicant Delay of 107 days (line 16 of Exhibit A) to 38 days (line 12 of Exhibit C), which is equivalent to the period of Applicant Delay beginning on the day that is 3 months after the date of the Notice to Comply (*i.e.*, June 2, 2002) and ending on the date the reply was filed by Applicants (*i.e.*, July 9, 2002).

(iii) Applicant Delay for Filing an Information Disclosure Statement

Applicants respectfully submit that an additional period of Applicant Delay of 12 days accrued for the delayed submission of an Information Disclosure Statement (IDS) on March 15, 2006 (see line 66, Exhibit C). This period is not shown on Exhibit A, the PTAS Sheet from the Office. As shown on Exhibit C, an IDS was filed without a statement under 37 CFR §1.704(d), 12 days after the filing of a response by Applicants to an office action on March 3, 2006. Pursuant to 37 CFR §1.704(c), this 12 day period should be considered an Applicant Delay and should be added to the period of delay by Applicants.

(iv) Other Entries Which Do Not Add to the Period of Applicant Delay

Applicants submit that there are several inconsistencies between entries shown on the PTAS Sheet (Exhibit A) and those shown on the Image File Wrapper Record (Exhibit B). In particular, Applicants direct the attention of the Office to Applicants' Petition to Correct Inventorship under 37 CFR §1.48(a) and accompanying Oath and Declaration filed on April 3, 2006. The Oath and Declaration is shown on Exhibit B, but does not appear on the PTAS Sheet (Exhibit A). According to MPEP 2732, oaths and declarations are examples of "other paper" that may generate reductions pursuant to 37CFR §1.704(c) (10) if such papers are filed after a Notice of Allowance is mailed or given. However, as Applicants filed the Oath and Declaration

USSN 10/010,942

Group Art Unit: 1649

on April 3, 2006, well before the Notice of Allowance mail date of May 11, 2006, and this submission is not believed to otherwise delay the processing or examination of the application (as evidenced by the issuance of a Notice of Allowance 38 days following receipt of the Oath and Declaration), it is not believed to be an Applicant Delay as defined by 37 CFR §1.704.

In addition to these inconsistencies, Applicants also wish to point out that the entries of May 10, 2006 and May 11, 2006 on the PTAS sheet entitled "Formal Drawings Required" and "Mail Formal Drawings Required," respectively, are erroneous. These entries do not appear in the Image File Wrapper Record (Exhibit B) and Applicants did not receive a paper copy of a request for formal drawing from the Office. Applicants contacted Examiner Ballard on August 1, 2006, in which she confirmed that she did not issue a notice for formal drawings and that the entry on the PTAS Sheet was erroneous. Applicants were informed by the Examiner that the Office would seek appropriate correction of these erroneous entries related to formal drawings. As shown in the Transaction History from Applicants Private PAIR (Exhibit F), the Office entered "~~Correction-Drawing~~ NOT required" on August 8, 2006, thereby acknowledging the erroneous entry in the PTAS Sheet. The preceding inconsistencies in the PTAS Sheet are noted in Exhibit C and appropriate correction by the Office is respectfully requested.

(v) Calculation of the Total Period of Applicant Delay

In view of the above, Applicants have calculated a total period of Applicant Delay of 335 days which is the sum of the following Applicant Delays shown in Exhibit C: (i) the 38 day period from June 2, 2002 to July 9, 2002 (lines 9-11); (ii) the 79 day period (line 29); (iii) the 92 day period (line 35); (iii) the 20 day period (line 39); (iv) the 30 day period (line 44); (v) the 5 day period (line 51); (vi) the 59 day period (line 63); and (vii) the 12 day period from March 3, 2006 to March 15, 2006 (lines 63-66). Applicants respectfully submit that the correct period of Applicant Delay is 335 days, not 392 days, and request appropriate correction by the Office.

USSN 10/010,942

Group Art Unit: 1649

C. Calculation of Correct Patent Term Adjustment Pursuant to 37 CFR §1.702(f)

As set forth in 37 CFR §1.703(f), Applicants are entitled to a period of patent term adjustment equal to the period of examination delays reduced by the period of Applicant Delay. Therefore, Applicants submit that the correct patent term adjustment for the above-referenced application is at least 508 days, which is the difference between the total period of examination delay (843 days) and the period of Applicant Delay (335 days). Applicants further submit that the term of 508 days should be extended by an additional term equal to the number of days following payment of the issue fee on August 11, 2006 to the date of issuance of a patent for the above-referenced application in accordance with 37 CFR §1.703(b). As such, the correct patent term adjustment upon issuance of a patent is expected to be the sum of 508 days (as calculated herein) and the number of days from August 12, 2006 to issuance of a patent.

4. In accordance with 37 CFR §1.705(b)(2)(iii), Applicants submit that the pending patent corresponding to this application will not be subject to a terminal disclaimer.

In view of the foregoing, it is respectfully requested that this Application for Patent Term Adjustment be favorably considered and that a corrected Determination of Patent Term Adjustment be issued to reflect a minimum patent term adjustment of 508 days, with an additional term to be added based on the number of days following payment of the issue fee on August 11, 2006 to the date of issuance of a patent for the above-referenced application.

Dated: August 10, 2006

Respectfully submitted,

By 

Amy E. Mandragouras, Esq.
Registration No.: 36,207
LAHIVE & COCKFIELD, LLP
28 State Street
Boston, Massachusetts 02109
(617) 227-7400
(617) 742-4214 (Fax)
Attorney For Applicant

EXHIBIT 3



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/010,942	12/06/2001	Guriq Basi	ELN-002

000959
LAHIVE & COCKFIELD
28 STATE STREET
BOSTON, MA 02109

CONFIRMATION NO. 5594

FORMALITIES LETTER



OC000000008658514

Date Mailed: 08/21/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice **MUST** be returned with the reply.

Customer Service Center
Initial Patent Examination Division (703) 308-1202

PART 3 - OFFICE COPY

CRF Problem Report

The Scientific and Technical Information Center (STIC) experienced a problem when processing the following computer readable form (CRF):

Application Serial Number: 10/010,942A
 Filing Date: 12/06/2001
 Date Processed by STIC: 1/24/2002

STIC Contact: Mark Spencer, 703-308-4212

Nature of Problem:

The CRF (was):

- ☒ (circle one) Damaged or Unreadable (for Unreadable, see attached)
☐ Blank (no files on CRF) (see attached)
☐ Empty file (filename present, but no bytes in file) (see attached)
☐ Virus-infected. Virus name: _____ The STIC will not process the CRF.
☐ Not saved in ASCII text
☐ Sequence Listing was embedded in the file. According to Sequence Rules, submitted file should only be the Sequence Listing.
☐ Did not contain a Sequence Listing. (see attached sample)
☐ Other: _____

**PLEASE USE THE CHECKER VERSION 3.1 PROGRAM TO REDUCE ERRORS.
 SEE BELOW FOR ADDRESS:**

<http://www.uspto.gov/web/offices/pac/checker>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail. Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom. Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/ebc/efs/downloads/documents.htm>> , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. Hand Carry directly to:
 U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name,
 Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202
 Or
 U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two,
 2011 South Clark Place, Arlington, VA 22202
4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office,
 Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 01/29/2002



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D C 20231
www.uspto.gov

**ATTACHMENT TO "NOTICE TO COMPLY WITH
REQUIREMENTS...SEQUENCE DISCLOSURES"**

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be submitted using one of the following methods:

1. Electronically submitted through EFS-Bio
(<http://www.uspto.gov/ebs/efs/downloads/documents.htm>, EFS Submission User Manual - ePAVE)
2. Mailed to:
U.S. Patent and Trademark Office
Box Sequence, P.O. Box 2327
Arlington, VA 22202
3. Mailed by Federal Express, United Parcel Service or other delivery service to:
U. S. Patent and Trademark Office
2011 South Clark Place
Customer Window, Box Sequence
Crystal Plaza Two, Lobby, Room 1B03
Arlington, Virginia 22202
4. Hand Carried directly to the Customer Window at:
2011 South Clark Place
Crystal Plaza Two, Lobby, Room 1B03, Box Sequence,
Arlington, Virginia 22202

Rev. 12/27/2001

EXHIBIT 4

THE "RECEIVED" STAMP OF THE PATENT AND TRADEMARK OFFICE
IMPRINTED HEREON ACKNOWLEDGES THE FILING OF:

Office No. ELN-902

Description of Paper¹ and No.: Transmittal Letter (1 page, in duplicate); Request for Two-Month Extension of Time (1 page, in duplicate); Response to Notice to File Missing Parts (2 pages, in duplicate); executed Declaration, Petition and Power of Attorney document (5 pages); Copy of Notice to file Missing Parts (5 pages); Preliminary Amendment (22 pages with Appendix A); Transmittal Letter for Diskette containing Substitute Sequence Listing (1 page); 21 pages of Substitute Sequence Listing; Diskette containing computer readable form of the Sequence Listing; and acknowledgment postcard.

Title: *Humanized Antibodies That Recognize Beta Amyloid Peptide*


Name of Applicant(s): Gurig Basi, Jose Saldana, and Ted Yednock

Int'l. or Serial No.: 10/010,942

Date: July 1, 2002


Attorneys: AEM/DMA/CEH

with Certificate of First Class Mailing



NO POSTAGE STAMP NECESSARY
POSTAGE HAS BEEN PREPAID BY

LAHIVE & COCKFIELD, LLP
28 STATE STREET
BOSTON, MA 02109



02109+1784 07

EXHIBIT 5

LAHIVE & COCKFIELD, LLP
28 State Street
Boston, MA 02109

SEQUENCE LISTING UNDER 37 CFR 1.825
(CORRECTED SEQUENCE)

Applicants: Basu, Gurig et al
Serial No. 10/010 942
Filed: 2001-12-06
For: HUMANIZED ANTIBODIES THAT
RECOGNIZE BETA-AMYLOID PEPTIDE
Copy: Lahive & Cockfield, LLP
Docket No. ELN-002 Date July 1, 2002

3 5" Diskette 1.44 MB IBM-PC MS-Windows

ELN-002

EXHIBIT 6

SEQUENCE LISTING

<110> Basi, Gurig
Saldanha, Jose
Yednock, Ted

<120> HUMANIZED ANTIBODIES THAT RECOGNIZE
BETA-AMYLOID PEPTIDE

<130> ELN-002

<140> US 10/010,942

<141> 2001-12-06

<150> US 60/251,892

<151> 2000-12-06

<160> 63

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 396

<212> DNA

<213> Mus musculus

<220>

<221> CDS

<222> (1)...(396)

<221> sig_peptide

<222> (1)...(60)

<400> 1

atg atg agt cct gcc cag ttc ctg ttt ctg tta gtc ctc tgg att cgg	48
Met Met Ser Pro Ala Gln Phe Leu Phe Leu Leu Val Leu Trp Ile Arg	
-20 -15 -10 -5	
gaa acc aac ggt tat gtc gtc atg acc cag act cca ctc acc ttg tgg	96
Glu Thr Asn Gly Tyr Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser	
1 5 10	
gtt acc att gga caa cca gcc tcc atc tct tgc aag tca agt cag agc	144
Val Thr Ile Gly Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser	
15 20 25	
ctc tta gat agt gat gga aag aca tat ttg aat tgg ttg tta cag agg	192
Leu Leu Asp Ser Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg	
30 35 40	
cca ggc cag tct cca aag cgc cta atc tat ctg gtc tct aaa ctg gac	240
Pro Gly Gln Ser Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp	
45 50 55 60	
tct gga gtc cct gac agg ttc act ggc agt gga tca ggg aca gat ttt	288
Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe	
65 70 75	
aca ctg aaa atc agc aga ata gag gct gag gat ttg gga ctt tat tat	336
Thr Leu Lys Ile Ser Arg Ile Glu Ala Glu Asp Leu Gly Leu Tyr Tyr	
80 85 90	
tgc tgg caa ggt aca cat ttt cct cgg acg ttc ggt gga ggc acc aag	384

ELN-002

Cys Trp Gln Gly Thr His Phe Pro Arg Thr Phe Gly Gly Gly Thr Lys
 95 100 105

ctg gaa atc aaa
 Leu Glu Ile Lys
 110

396

<210> 2
 <211> 132
 <212> PRT
 <213> Mus musculus

<220>
 <221> SIGNAL
 <222> (1)...(20)

<400> 2
 Met Met Ser Pro Ala Gln Phe Leu Phe Leu Leu Val Leu Trp Ile Arg
 -20 -15 -10 -5
 Glu Thr Asn Gly Tyr Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser
 1 5 10
 Val Thr Ile Gly Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser
 15 20 25
 Leu Leu Asp Ser Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg
 30 35 40
 Pro Gly Gln Ser Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp
 45 50 55 60
 Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe
 65 70 75
 Thr Leu Lys Ile Ser Arg Ile Glu Ala Glu Asp Leu Gly Leu Tyr Tyr
 80 85 90
 Cys Trp Gln Gly Thr His Phe Pro Arg Thr Phe Gly Gly Gly Thr Lys
 95 100 105
 Leu Glu Ile Lys
 110

<210> 3
 <211> 414
 <212> DNA
 <213> Mus musculus

<220>
 <221> CDS
 <222> (1)...(414)

<221> sig_peptide
 <222> (1)...(57)

<400> 3
 atg aac ttc ggg ctc agc ttg att ttc ctc gtc ctt gct tta aaa ggc 48
 Met Asn Phe Gly Leu Ser Leu Ile Phe Leu Val Leu Val Leu Lys Gly
 -15 -10 -5
 gtc cag tgc gaa gtg aag ctg gtc gag tct ggg gga ggc tta gtc aag 96
 Val Gln Cys Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys
 1 5 10
 cct gga ggc tct ctg aaa ctc tcc tgt gca gcc tct gga ttc acc ttc 144
 Pro Gly Ala Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
 15 20 25

ELN-002

```

agt aac rat ggc atg tct tgg gtt cgc cag aat tca gac aag agg ctg 192
Ser Asn Tyr Gly Met Ser Trp Val Arg Gln Asn Ser Asp Lys Arg Leu
 30          35          40          45

gag tgg gtt gca tcc att agg agt ggt ggt ggt aga acc tac tat tca 240
Glu Trp Val Ala Ser Ile Arg Ser Gly Gly Gly Arg Thr Tyr Tyr Ser
          50          55          60

gac aat gta aag ggc cga ttc acc atc tcc aga gag aat gcc aag aac 288
Asp Asn Val Lys Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn
          65          70          75

acc ctg tac ctg caa atg agt agt ctg aag tct gag gac acg gcc tct 336
Thr Leu Tyr Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Leu
          80          85          90

tat tat tgt gtc aga tat gat cac tat agt ggt agc tcc gac tac tgg 384
Tyr Tyr Cys Val Arg Tyr Asp His Tyr Ser Gly Ser Ser Asp Tyr Trp
          95          100          105

ggc cag ggc acc act gtc aca gtc tcc tca 414
Gly Gln Gly Thr Thr Val Thr Val Ser Ser
110          115

```

<210> 4
 <211> 138
 <212> PRT
 <213> Mus musculus

<220>
 <221> SIGNAL
 <222> (1)...(19)

```

<400> 4
Met Asn Phe Gly Leu Ser Leu Ile Phe Leu Val Leu Val Leu Lys Gly
-15          -10          -5
Val Gln Cys Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys
 1          5          10
Pro Gly Ala Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
15          20          25
Ser Asn Tyr Gly Met Ser Trp Val Arg Gln Asn Ser Asp Lys Arg Leu
30          35          40          45
Glu Trp Val Ala Ser Ile Arg Ser Gly Gly Gly Arg Thr Tyr Tyr Ser
          50          55          60
Asp Asn Val Lys Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn
          65          70          75
Thr Leu Tyr Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Leu
          80          85          90
Tyr Tyr Cys Val Arg Tyr Asp His Tyr Ser Gly Ser Ser Asp Tyr Trp
          95          100          105
Gly Gln Gly Thr Thr Val Thr Val Ser Ser
110          115

```

<210> 5
 <211> 132
 <212> PRT
 <213> Artificial Sequence

<220>
 <221> SIGNAL
 <222> (1)...(20)

ELN-002

<223> humanized 3D6 light chain variable region

<400> 5

```

Met Met Ser Pro Ala Gln Phe Leu Phe Leu Leu Val Leu Trp Ile Arg
-20          -15          -10          -5
Glu Thr Asn Gly Tyr Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro
          1          5          10
Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser
          15          20          25
Leu Leu Asp Ser Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Lys
          30          35          40
Pro Gly Gln Ser Pro Gln Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp
45          50          55          60
Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe
          65          70          75
Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr
          80          85          90
Cys Trp Gln Gly Thr His Phe Pro Arg Thr Phe Gly Gln Gly Thr Lys
          95          100          105
Val Glu Ile Lys
          110

```

<210> 6

<211> 125

<212> PRT

<213> Homo sapiens

<220>

<221> SIGNAL

<222> (1)...(13)

<400> 6

```

Met Gly Leu Leu Met Leu Trp Val Ser Gly Ser Ser Gly Asp Ile Val
          -10          -5          1
Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala
          5          10          15
Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr
20          25          30          35
Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu
          40          45          50
Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe
          55          60          65
Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val
          70          75          80
Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr
          85          90          95
Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100          105          110

```

<210> 7

<211> 100

<212> PRT

<213> Homo sapiens

<400> 7

```

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
          1          5          10          15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
          20          25          30
Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
          35          40          45

```


ELN-002

```

Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
  50          55          60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
  65          70          75          80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
          85          90          95
Leu Gln Thr Pro
          100

```

<210> 8
 <211> 138
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Humanized 3D6 heavy chain variable region
 <221> SIGNAL
 <222> (1)...(19)

```

<400> 8
Met Asn Phe Gly Leu Ser Leu Ile Phe Leu val Leu val Leu Lys Gly
          -15          -10          -5
Val Gln Cys Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln
          1          5          10
Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
  15          20          25
Ser Asn Tyr Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
  30          35          40          45
Glu Trp Val Ala Ser Ile Arg Ser Gly Gly Gly Arg Thr Tyr Tyr Ser
          50          55          60
Asp Asn Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn
          65          70          75
Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu
          80          85          90
Tyr Tyr Cys Val Arg Tyr Asp His Tyr Ser Gly Ser Ser Asp Tyr Trp
          95          100          105
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
  110          115

```

<210> 9
 <211> 121
 <212> PRT
 <213> Homo sapiens

```

<400> 9
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
  1          5          10          15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
          20          25          30
Ala Val Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
          35          40          45
Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
          50          55          60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
          65          70          75          80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys
          85          90          95
Ala Lys Asp Asn Tyr Asp Phe Trp Ser Gly Thr Phe Asp Tyr Trp Gly
          100          105          110
Gln Gly Thr Leu Val Thr Val Ser Ser

```

ELN-002

115

120

<210> 10
 <211> 98
 <212> PRT
 <213> Homo sapiens

<400> 10
 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30
 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Lys

<210> 11
 <211> 132
 <212> PRT
 <213> Artificial Sequence

<220>
 <221> SIGNAL
 <222> (1)...(20)

<223> humanized 3D6 light chain variable region

<400> 11
 Met Met Ser Pro Ala Gln Phe Leu Phe Leu Leu Val Leu Trp Ile Arg
 -20 -15 -10 -5
 Glu Thr Asn Gly Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro
 1 5 10
 Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser
 15 20 25
 Leu Leu Asp Ser Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Lys
 30 35 40
 Pro Gly Gln Ser Pro Gln Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp
 45 50 55 60
 Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe
 65 70 75
 Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr
 80 85 90
 Cys Trp Gln Gly Thr His Phe Pro Arg Thr Phe Gly Gln Gly Thr Lys
 95 100 105
 Val Glu Ile Lys
 110

<210> 12
 <211> 138
 <212> PRT
 <213> Artificial Sequence

<220>

ELN-002

<223> Humanized 3D6 light chain variable region

<221> SIGNAL

<222> (1)...(19)

<400> 12

```

Met Asn Phe Gly Leu Ser Leu Ile Phe Leu Val Leu Val Leu Lys Gly
          -15          -10          -5
Val Gln Cys Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln
          1          5          10
Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
          15          20          25
Ser Asn Tyr Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
          30          35          40          45
Glu Trp Val Ala Ser Ile Arg Ser Gly Gly Gly Arg Thr Tyr Tyr Ser
          50          55          60
Asp Asn Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
          65          70          75
Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
          80          85          90
Tyr Tyr Cys Val Arg Tyr Asp His Tyr Ser Gly Ser Ser Asp Tyr Trp
          95          100          105
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
110          115

```

<210> 13

<211> 393

<212> DNA

<213> Mus musculus

<220>

<221> CDS

<222> (1)...(393)

<221> sig_peptide

<222> (1)...(57)

<400> 13

```

atg aag ctg cct gtt agg ctg ttg gta ctg atg ttc tgg att cct gcc 48
Met Lys Leu Pro Val Arg Leu Leu Val Leu Met Phe Trp Ile Pro Ala
          -15          -10          -5

tcc agc agt gat gtt ttg atg acc caa act cca ctc tcc ctg cct gtc 96
Ser Ser Ser Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val
          1          5          10

agt ctt gga gat caa gcc tcc atc tct tgc aga tct agt cag aac att 144
Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Asn Ile
          15          20          25

ata cat agt aac gga aac acc tat tta gaa tgg tac ctg cag aaa cca 192
Ile His Ser Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro
          30          35          40          45

ggc cag tct cca aag ctc ctg atc tac aaa gtc tcc aac cga ttc tct 240
Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser
          50          55          60

ggg gtc cca gac agg ttc agt ggc agt gga tca ggg aca gat ttc aca 288
Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
          65          70          75

```

ELN-002

```

ctc aag atc aag aaa gtg gag gct gag gat ctg gga att cat cac tgc 336
Leu Lys Ile Lys Lys Val Glu Ala Glu Asp Leu Gly Ile Tyr Tyr Cys
      80              85              90

ttt caa ggt tca cat gtc ccg ctc acg ttc ggt gct ggg acc aag ctg 384
Phe Gln Gly Ser His Val Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu
      95              100             105

gag ctg gaa 393
Glu Leu Glu
110

```

```

<210> 14
<211> 131
<212> PRT
<213> Mus musculus

```

```

<220>
<221> SIGNAL
<222> (1)...(19)

```

```

<400> 14
Met Lys Leu Pro Val Arg Leu Leu Val Leu Met Phe Trp Ile Pro Ala
      -15              -10              -5
Ser Ser Ser Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val
      1              5              10
Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Asn Ile
      15              20              25
Ile His Ser Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro
      30              35              40              45
Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser
      50              55              60
Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
      65              70              75
Leu Lys Ile Lys Lys Val Glu Ala Glu Asp Leu Gly Ile Tyr Tyr Cys
      80              85              90
Phe Gln Gly Ser His Val Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu
      95              100             105
Glu Leu Glu
110

```

```

<210> 15
<211> 426
<212> DNA
<213> Mus musculus

```

```

<220>
<221> CDS
<222> (1)...(426)

```

```

<221> sig_peptide
<222> (1)...(57)

```

```

<400> 15
atg gac agg ctt act tcc tca ttc ctg ctg ctg att gtc cct gca tac 48
Met Asp Arg Leu Thr Ser Ser Phe Leu Leu Leu Ile Val Pro Ala Tyr
      -15              -10              -5

gtc ctg tcc cag gct act ctg aaa gag tct ggc cct gga ata ttg cag 96
Val Leu Ser Gln Ala Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Gln
      1              5              10

```

ELN-002

```

ccc tcc cag acc ctc agt ctg act tgc tct ttc tct ggg ttt tca ctg 144
Ser Ser Gln Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu
      15                20                25

agc act tct ggt atg gga ctg agc tgg att cgt cag cct tca gga aag 192
Ser Thr Ser Gly Met Gly Val Ser Trp Ile Arg Gln Pro Ser Gly Lys
      30                35                40                45

ggc ctg gag tgg ctg gca cac att tac tgg gat gat gac aag cgc tac 240
Gly Leu Glu Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr
      50                55                60

aac cca tcc ctg aag agc cgg ctg aca atc tcc aag gat acc tcc aga 288
Asn Pro Ser Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Arg
      65                70                75

aag cag gta ttc ctc aag atc acc agt gtc gac cct gca gat act gcc 336
Lys Gln Val Phe Leu Lys Ile Thr Ser Val Asp Pro Ala Asp Thr Ala
      80                85                90

aca tac tac tgt gtc cga agg ccc att act ccg gta cta gtc gat gcc 384
Thr Tyr Tyr Cys Val Arg Arg Pro Ile Thr Pro Val Leu Val Asp Ala
      95                100                105

atg gac tac tgg ggt caa gga acc tca gtc acc gtc tcc tca 426
Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser
      110                115                120

```

<210> 16
 <211> 142
 <212> PRT
 <213> Mus musculus

<220>
 <221> SIGNAL
 <222> (1)...(19)

```

<400> 16
Met Asp Arg Leu Thr Ser Ser Phe Leu Leu Leu Ile Val Pro Ala Tyr
      -15                -10                -5
Val Leu Ser Gln Ala Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Gln
      1                5                10
Ser Ser Gln Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu
      15                20                25
Ser Thr Ser Gly Met Gly Val Ser Trp Ile Arg Gln Pro Ser Gly Lys
      30                35                40                45
Gly Leu Glu Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr
      50                55                60
Asn Pro Ser Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Arg
      65                70                75
Lys Gln Val Phe Leu Lys Ile Thr Ser Val Asp Pro Ala Asp Thr Ala
      80                85                90
Thr Tyr Tyr Cys Val Arg Arg Pro Ile Thr Pro Val Leu Val Asp Ala
      95                100                105
Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser
      110                115                120

```

<210> 17
 <211> 136
 <212> DNA

ELN-002

<213> Artificial Sequence

<220>

<223> primer

<400> 17

tccgcaagct tgcgcacc accagacatgc gcgtgcccgc ccagctgctg ggccctgctga 60
 tgctgtgggt gtccggctcc tccggctacg tggatgatgac ccagcccccc ctgtccctgc 120
 ccgtgacccc cggcga 136

<210> 18

<211> 131

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 18

ctgggggggac tggccgggct tctgcagcag ccagctcagg taggtcttgc cgtcggagtc 60
 cagcagggac tgggaggact tgcaggagat ggaggcgggc tgcggggggg tcacggggcag 120
 ggacaggggg g 131

<210> 19

<211> 146

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 19

acctgaactg gctgctgcag aagcccgggc agtcccccca ggcctcgatc tacctgggtgt 60
 ccaagctgga ctccggcgtg cccgaccgct tctccggctc cggctccggc accgacttca 120
 cctgaagat ctcccgctg gaggcc 146

<210> 20

<211> 142

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 20

aattctagga tccactcacg ctctgatctcc accttgggtgc cctggccgaa ggtgcggggg 60
 aagtggtgct cctgccagca gtagtacacg cccacgtcct cggctccac gcgggagatc 120
 ttcagggtga agtcgggtgcc gg 142

<210> 21

<211> 16

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 21

ctgggggggac tggccg 16

<210> 22

<211> 22

<212> DNA

ELN-002

<213> Artificial Sequence

<220>

<223> primer

<400> 22

acctgaactg gctgctgcag aa

22

<210> 23

<211> 138

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 23

acagaaagct tgcgcacc accatggagcttg ggctgagctg gctttttctt gtggctattc 60
 caaaaggtgc ccagtgtgag gtgcagctgc tggagtccgg cggcggcctg gtgcagcccg 120
 gcggctccct gcgcctgc 138

<210> 24

<211> 135

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 24

gccgcccagc cggatggagg ccaccactc caggcccttg ccgggggctt ggcgcaccca 60
 ggacatgccg tagtggaga aggtgaagcc ggaggcggcg caggacaggc gcagggagcc 120
 gccgggctgc accag 135

<210> 25

<211> 142

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 25

ctggagtggg tggcctccat ccgctccggc ggcgcccgca cctactactc cgacaacgtg 60
 aagggccgct ccaccatctc ccgcgacaac gccagaact cctctgacct gcagatgaac 120
 tccctgcgcg ccgaggacac cg 142

<210> 26

<211> 144

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 26

ctgcaaggat ccactcaccg gaggacacgg ccaccagggt gccctggccc cagtagtcgg 60
 aggagccgga gtagtggtcg tagcgacgc agtagracag ggcggtgtcc tcggcgcgca 120
 gggagttcat ctgcaggcac aggg 144

<210> 27

<211> 16

<212> DNA

ELN-002

<213> Artificial Sequence

<220>

<223> primer

<400> 27

gccgccggag cggatg

16

<210> 28

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 28

ctggagtggg tggcctccat

20

<210> 29

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 29

tccgcaagct tggcgccac

19

<210> 30

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 30

aattctagga tccactcacg cttgaccc

29

<210> 31

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 31

acagaaagct tggcgccacc atg

23

<210> 32

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 32

ctgcaaggat ccactcacg ga

22

ELN-002

<210> 33
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> native ABeta peptide

<400> 33
Asp Ala Glu Phe Arg His Asp Ser Gly Tyr
1 5 10

<210> 34
<211> 402
<212> DNA
<213> Artificial Sequence

<220>
<223> h3D6 version 1 VL

<400> 34
atggacatgc gctgccccgc ccagctgctg ggcctgctga tgcctgctgggt gtcctggctcc 60
tccggctacg tggatgatgac ccagctcccc ctgtccctgc ccgtgacccc cggcgagccc 120
gctcccatct cctgcaagtc ctcccagctc ctgctggact ccgacggcaa gacctacctg 180
aaactggctgc tgcagaagcc cggccagctc cccagcgcc tgcctacctt ggtgtccaag 240
ctggactccg gctgccccga ccgcttctcc ggcctccggc ccggcaccga ctccacctg 300
aagatctccc gctgaggagg caggagcgtg ggcgtgtact actgctggca gggcaccac 360
tcccccgca ccttcggcca gggcaccag gtcgagatca ag 402

<210> 35
<211> 402
<212> DNA
<213> Artificial Sequence

<220>
<223> h3D6 version 2 VL

<400> 35
atggacatgc gctgccccgc ccagctgctg ggcctgctga tgcctgctgggt gtcctggctcc 60
tccggcgacg tggatgatgac ccagctcccc ctgtccctgc ccgtgacccc cggcgagccc 120
gctcccatct cctgcaagtc ctcccagctc ctgctggact ccgacggcaa gacctacctg 180
aaactggctgc tgcagaagcc cggccagctc cccagcgcc tgcctacctt ggtgtccaag 240
ctggactccg gctgccccga ccgcttctcc ggcctccggc ccggcaccga ctccacctg 300
aagatctccc gctgaggagg caggagcgtg ggcgtgtact actgctggca gggcaccac 360
tcccccgca ccttcggcca gggcaccag gtcgagatca ag 402

<210> 36
<211> 414
<212> DNA
<213> Artificial Sequence

<220>
<223> h3D6 version 1 VH

<400> 36
atggagcttg ggcctgagctg gctttttctt gtggctatct taaaaggctc ccagtgtgag 60
gtgcagctgc tggagctccg cggcggcctg gtgcagcccg gcggctccct gcgcctgtcc 120
tgcgcgcctt ccggctttac cttctccaac tacggcatgt cctgggtgct ccaggccccc 180
ggcaaggggc tggagtggtt ggcctccatc cgtccggcg gcggccgcac ctactacctc 240
gacaacgtga agggccgctt caccatctcc cgcgacaacg ccaagaactc cctgtacctg 300
cagatgaact ccttgcgcgc caggagacac gccctgtact actgcgtgct ctacgaccac 360
tactccggct cctccgacta ctggggccag ggcacccctg taccctgtct ctcc 414

ELN-002

<210> 37
 <211> 414
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> h3D6 version 2 VH

<400> 37
 atggagcttgg ggtgagctg gctcttctctt ggtgctatct taaaagggtgt ccagtgtgag 60
 gtgcagctgc tggagctcgg cggcggcctg gtgcagcccg gcggctccct gcgcctgtcc 120
 tgcgcgcctt ccggcttcac ctctcccaac tacggcatgt cctgggtgcg ccaggccccc 180
 ggcaaggggc tggagtggtt ggcctccatc cgtcccggtg gcggccgcac ctactactcc 240
 gacaacgtga agggccgctt caccatctcc cgcgacaact ccaagaacac cctgtacctg 300
 cagatgaact cctgcgcgc caggagacac gccgtgtact actgcgtgct ctacgaccac 360
 tactccggct cctccgacta ctggggccag ggcacctctg tgaccgtgtc ctcc 414

<210> 38
 <211> 770
 <212> PRT
 <213> Homo sapiens

<400> 38
 Met Leu Pro Gly Leu Ala Leu Leu Leu Leu Ala Ala Trp Thr Ala Arg
 1 5 10 15
 Ala Leu Glu Val Pro Thr Asp Gly Asn Ala Gly Leu Leu Ala Glu Pro
 20 25 30
 Gln Ile Ala Met Phe Cys Cys Arg Leu Asn Met His Met Asn Val Gln
 35 40 45
 Asn Gly Lys Trp Asp Ser Asp Pro Ser Gly Thr Lys Thr Cys Ile Asp
 50 55 60
 Thr Lys Glu Gly Ile Leu Gln Tyr Cys Gln Glu Val Tyr Pro Glu Leu
 65 70 75 80
 Gln Ile Thr Asn Val Val Glu Ala Asn Gln Pro Val Thr Ile Gln Asn
 85 90 95
 Trp Cys Lys Arg Gly Arg Lys Gln Cys Lys Thr His Pro His Phe Val
 100 105 110
 Ile Pro Tyr Arg Cys Leu Val Gly Glu Phe Val Ser Asp Ala Leu Leu
 115 120 125
 Val Pro Asp Lys Cys Lys Phe Leu His Gln Glu Arg Met Asp Val Cys
 130 135 140
 Glu Thr His Leu His Trp His Thr Val Ala Lys Glu Thr Cys Ser Glu
 145 150 155 160
 Lys Ser Thr Asn Leu His Asp Tyr Gly Met Leu Leu Pro Cys Gly Ile
 165 170 175
 Asp Lys Phe Arg Gly Val Glu Phe Val Cys Cys Pro Leu Ala Glu Glu
 180 185 190
 Ser Asp Asn Val Asp Ser Ala Asp Ala Glu Glu Asp Asp Ser Asp Val
 195 200 205
 Trp Trp Gly Gly Ala Asp Thr Asp Tyr Ala Asp Gly Ser Glu Asp Lys
 210 215 220
 Val Val Glu Val Ala Glu Glu Glu Glu Val Ala Glu Val Glu Glu Glu
 225 230 235 240
 Glu Ala Asp Asp Asp Glu Asp Asp Glu Asp Gly Asp Glu Val Glu Glu
 245 250 255
 Glu Ala Glu Glu Pro Tyr Glu Glu Ala Thr Glu Arg Thr Thr Ser Ile
 260 265 270
 Ala Thr Thr Thr Thr Thr Thr Thr Glu Ser Val Glu Glu Val Val Arg
 275 280 285
 Glu Val Cys Ser Glu Gln Ala Glu Thr Gly Pro Cys Arg Ala Met Ile
 290 295 300
 Ser Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys Ala Pro Phe Phe

ELN-002

```

305          310          315          320
Tyr Gly Gly Cys Gly Gly Asn Arg Asn Asn Phe Asp Thr Glu Glu Tyr
          325          330          335
Cys Met Ala Val Cys Gly Ser Ala Met Ser Gln Ser Leu Leu Lys Thr
          340          345          350
Thr Gln Glu Pro Leu Ala Arg Asp Pro Val Lys Leu Pro Thr Thr Ala
          355          360          365
Ala Ser Thr Pro Asp Ala Val Asp Lys Tyr Leu Glu Thr Pro Gly Asp
          370          375          380
Glu Asn Glu His Ala His Phe Gln Lys Ala Lys Glu Arg Leu Glu Ala
385          390          395          400
Lys His Arg Glu Arg Met Ser Gln Val Met Arg Glu Trp Glu Glu Ala
          405          410          415
Glu Arg Gln Ala Lys Asn Leu Pro Lys Ala Asp Lys Lys Ala Val Ile
          420          425          430
Gln His Phe Gln Glu Lys Val Glu Ser Leu Glu Gln Glu Ala Ala Asn
          435          440          445
Glu Arg Gln Gln Leu Val Glu Thr His Met Ala Arg Val Glu Ala Met
          450          455          460
Leu Asn Asp Arg Arg Arg Leu Ala Leu Glu Asn Tyr Ile Thr Ala Leu
465          470          475          480
Gln Ala Val Pro Pro Arg Pro Arg His Val Phe Asn Met Leu Lys Lys
          485          490          495
Tyr Val Arg Ala Glu Gln Lys Asp Arg Gln His Thr Leu Lys His Phe
          500          505          510
Glu His Val Arg Met Val Asp Pro Lys Lys Ala Ala Gln Ile Arg Ser
          515          520          525
Gln Val Met Thr His Leu Arg Val Ile Tyr Glu Arg Met Asn Gln Ser
          530          535          540
Leu Ser Leu Leu Tyr Asn Val Pro Ala Val Ala Glu Glu Ile Gln Asp
545          550          555          560
Glu Val Asp Glu Leu Leu Cln Lys Glu Gln Asn Tyr Ser Asp Asp Val
          565          570          575
Leu Ala Asn Met Ile Ser Cln Pro Arg Ile Ser Tyr Gly Asn Asp Ala
          580          585          590
Leu Met Pro Ser Leu Thr Glu Thr Lys Thr Thr Val Glu Leu Leu Pro
          595          600          605
Val Asn Gly Glu Phe Ser Leu Asp Asp Leu Gln Pro Trp His Ser Phe
          610          615          620
Gly Ala Asp Ser Val Pro Ala Asn Thr Glu Asn Glu Val Glu Pro Val
625          630          635          640
Asp Ala Arg Pro Ala Ala Asp Arg Gly Leu Thr Thr Arg Pro Gly Ser
          645          650          655
Gly Leu Thr Asn Ile Lys Thr Glu Glu Ile Ser Glu Val Lys Met Asp
          660          665          670
Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys Leu
          675          680          685
Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile Gly
          690          695          700
Leu Met Val Gly Gly Val Val Ile Ala Thr Val Ile Val Ile Thr Leu
705          710          715          720
Val Met Leu Lys Lys Lys Gln Tyr Thr Ser Ile His His Gly Val Val
          725          730          735
Glu Val Asp Ala Val Thr Pro Glu Glu Arg His Leu Ser Lys Met
          740          745          750
Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys Phe Phe Glu Gln Met
          755          760          765
Gln Asn
          770

```

<210> 39

<211> 40

ELN-002

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 39

actagtcgac atgaagtcgc ctgttaggct gctggcgctg

40

<210> 40

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 40

actagtcgac atggagwcag acacactcct gytatgggt

39

<210> 41

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 41

actagtcgac atgagtgtgc tcactcaggt cctggsggtg

40

<210> 42

<211> 43

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 42

actagtcgac atgaggrocc ctgctcagwc tyttggmwtc ttg

43

<210> 43

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 43

actagtcgac atggatttgc aggtgcagat twwcagcttc

40

<210> 44

<211> 37

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 44

actagtcgac atgaggckcy ytcytsagyt yctgrgg

37

ELN-002

<210> 45
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 45
actagtcgac atggggcwtca agatggagtc acakwyycwg g 41

<210> 46
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 46
actagtcgac atgtggggay cckcttcyemm tctctcaatt g 41

<210> 47
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 47
actagtcgac atgggttcow caactcagtt ccttg 35

<210> 48
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 48
actagtcgac atgtatatat gttctgtgtc tatctct 37

<210> 49
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 49
actagtcgac atggaagccc cagctcagct tctctctc 38

<210> 50
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

ELN-002

<400> 50
ggatccccggg tggatggcgg gaagatg 27

<210> 51
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 51
actagtcgac atgaaatgca gctgggcatc attcttc 37

<210> 52
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 52
actagtcgac atgggatgga gcttcatcat sycttc 36

<210> 53
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 53
actagtcgac atgaagwtgt ggttaaaactg ggttttt 37

<210> 54
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 54
actagtcgac atgractctg ggytcagctt grctt 35

<210> 55
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 55
actagtcgac atggactcca ggctcaattt agtcttcctt 40

<210> 56
<211> 37
<212> DNA
<213> Artificial Sequence

ELN-002

<220>

<223> primer

<400> 56

actagtcgac atggetgtcy tnygctctcc cctctgc 37

<210> 57

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 57

actagtcgac atggratgga gctggctccc cctctcc 36

<210> 58

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 58

actagtcgac atgagagtgc tgattccccc gtcg 33

<210> 59

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 59

actagtcgac atggmctggg tgtggamett gctattccctg 40

<210> 60

<211> 37

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 60

actagtcgac atgggcagac ttacattctc attcctg 37

<210> 61

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 61

actagtcgac atggattctg ggctgattcc tcttattg 38

<210> 62

ELN-002

<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 62
accagtcgac atgacggctgt caagtcttct gtaccctg

37

<210> 63
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 63
ggatccccggg agtggataga ctgacgg

27

EXHIBIT 7

PAGE: 1 VERIFICATION SUMMARY REPORT DATE:
02/23/2007 PATENT APPLICATION TIME:
10:39:24

INPUT SEQ: G:\Data\E\ELN\002\Petition for
Reconsideration\Sequence Listing\sequence listing text.txt

GENERAL INFORMATION SECTION

3,<110> Basi, Gurig
4. Saldanha, Jose
5. Yednock, Ted
7,<120> HUMANIZED ANTIBODIES THAT RECOGNIZE
8. BETA-AMYLOID PEPTIDE
10,<130> ELN-002
12,<140> US 10/010,942
13,<141> 2001-12-06
15,<150> US 60/251,892
16,<151> 2000-12-06
18,<160> 63
20,<170> FastSEQ for Windows Version 4.0

ERRORED LINES SECTION

STATISTICS SUMMARY

Application Serial Number: US 10/010,942
Alpha or Numeric: Numeric
Application Class:
Application File Date: 2001-12-06
Art Unit:
Software Application: FastSEQ
Total Number of Sequences: 63
Total Nucleotides: 5470
Total Amino Acids: 2307
Number of Errors: 0
Number of Warnings: 0
Number of Corrections: 0

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted by facsimile to the Patent and Trademark Office, Office of Petitions, facsimile no. (571) 273-8300 at Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.


Dated: February 26, 2007 Signature: 
(Amy E. Mandragoras)

EXHIBIT 8

Docket No.: ELN-002
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Guriq Basi *et al.*

Application No.: 10/010942

Confirmation No.: 5594

Filed: December 6, 2001

Art Unit: 1649

For: HUMANIZED ANTIBODIES THAT
RECOGNIZE BETA AMYLOID PEPTIDE

Examiner: Ballard, Kimberly A.

AFFIDAVIT BY MICAELA C. HILL

MS Petition
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I, Ms. Micaela C. Hill, declare the following:

1. I am presently a paralegal at the firm of Lahive & Cockfield LLP. I have been employed as a paralegal for approximately 1 year. My responsibilities include the preparation of Sequence Listings, including sequence diskettes, for submission to the United States Patent & Trademark Office (USPTO).
2. I have inspected Applicants' Attorney's file copy of the sequence diskette mailed on July 1, 2002 to the USPTO and confirm that it is in working condition and in computer-readable form.

Serial No. 10/010,942

ELN-002

3. I have used Applicants' Attorney's file copy of the diskette mailed July 1, 2002 to print a paper copy of the Sequence Listing contained thereon. The paper copy of Applicants' Attorney's file copy of the July 1, 2002 sequence diskette is submitted together with this Affidavit as Exhibit 6.

4. I hereby state that the content of Applicants' Attorney's file copy of the July 1, 2002 diskette and the paper copy of the Sequence Listing contained thereon are the same.

5. I declare further that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under §1001 of Title XVIII of the United States Code, and that such willful false statements may jeopardize the validity of this Application for Patent or any patent issuing thereon.

Date: February 26, 2007

Signed:


Micaela C. Hill

EXHIBIT 9

SeqListCorrected.txt
SEQUENCE LISTING

<110> Basi, Gurig
Saldanha, Jose
Yednock, Ted

<120> HUMANIZED ANTIBODIES THAT RECOGNIZE
BETA-AMYLOID PEPTIDE

<130> ELN-002

<140> US 10/010,942

<141> 2001-12-06

<150> US 60/251,892

<151> 2000-12-06

<160> 63

<170> FastSEQ for windows version 4.0

<210> 1

<211> 396

<212> DNA

<213> Mus musculus

<220>

<221> CDS

<222> (1)...(396)

<221> sig_peptide

<222> (1)...(60)

<400> 1 48
atg atg agt cct gcc cag ttc ctg ttt ctg tta gtg ctc tgg att cgg
Met Met Ser Pro Ala Gln Phe Leu Phe Leu Leu Val Leu Trp Ile Arg
-20 -15 -10 -5
gaa acc aac ggt tat gtt gtg atg acc cag act cca ctc act ttg tgg 96
Glu Thr Asn Gly Tyr Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser
1 5 10
gtt acc att gga caa cca gcc tcc atc tct tgc aag tca agt cag agc 144
Val Thr Ile Gly Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser
15 20 25
ctc tta gat agt gat gga aag aca tat ttg aat tgg ttg tta cag agg 192
Leu Leu Asp Ser Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg
30 35 40
cca gcc cag tct cca aag cgc cta atc tat ctg gtg tct aaa ctg gac 240
Pro Gly Gln Ser Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp
45 50 55 60
tct gga gtc cct gac agg ttc act ggc agt gga tca ggg aca gat ttt 288
Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe
65 70 75
aca ctg aaa atc agc aga ata gag gct gag gat ttg gga ctt tat tat 336
Thr Leu Lys Ile Ser Arg Ile Glu Ala Glu Asp Leu Gly Leu Tyr Tyr
80 85 90
tgc tgg caa ggt aca cat ttt cct cgg acg ttc ggt gga ggc acc aag 384
Page 1

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted by facsimile to the Patent and Trademark Office, Office of Petitions, Invention no. (571) 273-8300 as Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: February 26, 2007

Signature: *(Signature)*
(A. E. Manouguerra)

EXHIBIT 10

Docket No.: ELN-002
(PATENT)**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:
Guriq Basi *et al.*

Application No.: 10/010942

Confirmation No.: 5594

Filed: December 6, 2001

Art Unit: 1649

For: HUMANIZED ANTIBODIES THAT
RECOGNIZE BETA AMYLOID PEPTIDE

Examiner: Ballard, Kimberly A.

AFFIDAVIT BY PATRICIA ROBINSON

MS Petition
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I, Ms. Patricia Robinson, declare the following:

1. I am Associate Director of Intellectual Property at Elan Pharmaceuticals, Inc.¹.
2. At our instruction, Applicants' Attorney sends us duplicate copies of all correspondence filed with the USPTO, including sequence diskettes. I have inspected our file copy of the sequence diskette mailed by Applicants' Attorney on July 1, 2002 to the USPTO and confirm that it is in working condition and in computer-readable form.

¹ Elan Pharmaceuticals, Inc. is a wholly-owned subsidiary of Elan Corporation, plc. Elan Pharma International Ltd. is a co-assignee of record in the above-referenced application, is an indirect wholly-owned subsidiary of Elan Corporation, plc.

ELN-002

Serial No. 10/010,942

3. I have used our file copy of the diskette mailed by Applicants' Attorney's on July 1, 2002 to print a paper copy of the Sequence Listing contained thereon. The paper copy of our file copy of the July 1, 2002 sequence diskette is submitted together with this Affidavit as Exhibit 9.

4. I hereby state that the content of our file copy of the July 1, 2002 diskette and the paper copy of the Sequence Listing contained thereon are the same.

5. I declare further that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under §1001 of Title XVIII of the United States Code, and that such willful false statements may jeopardize the validity of this Application for Patent or any patent issuing thereon.

Date: February 26, 2007

Signed: 

seqlistCorrected.txt

cys Trp Gln Gly Thr His Phe Pro Arg Thr Phe Gly Gly Gly Thr Lys
 95 100 105 396

ctg gaa atc aaa
 Leu Glu Ile Lys
 110

<210> 2
 <211> 132
 <212> PRT
 <213> Mus musculus

<220>
 <221> SIGNAL
 <222> (1)...(20)

<400> 2
 Met Met Ser Pro Ala Gln Phe Leu Phe Leu Val Leu Trp Ile Arg
 -20 -15 -10 -5
 Glu Thr Asn Gly Tyr Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser
 1 5 10
 Val Thr Ile Gly Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser
 15 20 25
 Leu Leu Asp Ser Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg
 30 35 40
 Pro Gly Gln Ser Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp
 45 50 55 60
 Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Thr Asp Phe
 65 70 75
 Thr Leu Lys Ile Ser Arg Ile Glu Ala Glu Asp Leu Gly Leu Tyr Tyr
 80 85 90
 Cys Trp Gln Gly Thr His Phe Pro Arg Thr Phe Gly Gly Gly Thr Lys
 95 100 105
 Leu Glu Ile Lys
 110

<210> 3
 <211> 414
 <212> DNA
 <213> Mus musculus

<220>
 <221> CDS
 <222> (1)...(414)

<221> sig_peptide
 <222> (1)...(57)

<400> 3
 atg aac ttc ggg ctc agc ttg att ttc ctt gtc ctt gtc tta aaa ggt 48
 Met Asn Phe Gly Leu Ser Leu Ile Phe Leu Val Leu Val Leu Lys Gly
 -15 -10 -5
 gtc cag tgt gaa gtc aag ctg gtg gag tct ggg gga ggc tta gtg aag 96
 Val Gln Cys Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys
 1 5 10
 cct gga gcg tct ctg aaa ctc tcc tgt gca gcc tct gga ttc act ttc 144
 Pro Gly Ala Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
 15 20 25

seqlistCorrected.txt

```

agc aac tat ggc atg tct tgg gtt cgc cag aat tca gac aag agg ctg 192
Ser Asn Tyr Gly Met Ser Trp Val Arg Gln Asn Ser Asp Lys Arg Leu 45
30

gag tgg gtt gca tcc att agg agt ggt ggt ggt aga acc tac tat tca 240
Glu Trp Val Ala Ser Ile Arg Ser Gly Gly Gly Arg Thr Tyr Tyr Ser 60
50

gac aat gta aag ggc cga ttc acc atc tcc aga gag aat gcc aag aac 288
Asp Asn Val Lys Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn 75
65

acc ctg tac ctg caa atg agt agt ctg aag tct gag gac acg gcc ttg 336
Thr Leu Tyr Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Leu 90
80

tat tat tgt gtc aga tat gat cac tat agt ggt agc tcc gac tac tgg 384
Tyr Tyr Cys Val Arg Tyr Asp His Tyr Ser Gly Ser Ser Asp Tyr Trp 105
95

ggc cag ggc acc act gtc aca gtc tcc tca 414
Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115
110

```

<210> 4
 <211> 138
 <212> PRT
 <213> Mus musculus

<220>
 <221> SIGNAL
 <222> (1)...(19)

```

<400> 4
Met Asn Phe Gly Leu Ser Leu Ile Phe Leu Val Leu Val Leu Lys Gly
-15 -10 -5
Val Gln Cys Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys
1 10
Pro Gly Ala Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
15 20 25
Ser Asn Tyr Gly Met Ser Trp Val Arg Gln Asn Ser Asp Lys Arg Leu
30 35 40 45
Glu Trp Val Ala Ser Ile Arg Ser Gly Gly Gly Arg Thr Tyr Tyr Ser
50 55 60
Asp Asn Val Lys Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn
65 70 75
Thr Leu Tyr Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Leu
80 85 90
Tyr Tyr Cys Val Arg Tyr Asp His Tyr Ser Gly Ser Ser Asp Tyr Trp
95 100 105
Gly Gln Gly Thr Thr Val Thr Val Ser Ser
110 115

```

<210> 5
 <211> 132
 <212> PRT
 <213> Artificial sequence

<220>
 <221> SIGNAL
 <222> (1)...(20)

SeqListCorrected.txt

<223> humanized 3Db light chain variable region

<400> 5
 Met Met Ser Pro Ala Gln Phe Leu Phe Leu Leu val Leu Trp Ile Arg
 -20 -15 -10 -5
 Glu Thr Asn Gly Tyr val val Met Thr Gln Ser Pro Leu Ser Leu Pro
 1 5 10
 val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser
 15 20 25
 Leu Leu Asp Ser Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Lys
 30 35 40
 Pro Gly Gln Ser Pro Gln Arg Leu Ile Tyr Leu val Ser Lys Leu Asp
 45 50 55 60
 Ser Gly val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe
 65 70 75
 Thr Leu Lys Ile Ser Arg val Glu Ala Glu Asp val Gly val Tyr Tyr
 80 85 90
 Cys Trp Gln Gly Thr His Phe Pro Arg Thr Phe Gly Gln Gly Thr Lys
 95 100 105
 val Glu Ile Lys
 110

<210> 6
 <211> 125
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SIGNAL
 <222> (1)...(13)

<400> 6
 Met Gly Leu Leu Met Leu Trp val Ser Gly Ser Ser Gly Asp Ile val
 -10 -5 1
 Met Thr Gln Ser Pro Leu Ser Leu Pro val Thr Pro Gly Glu Pro Ala
 5 10 15
 Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr
 20 25 30 35
 Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu
 40 45 50
 Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly val Pro Asp Arg Phe
 55 60 65
 Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg val
 70 75 80
 Glu Ala Glu Asp val Gly val Tyr Tyr Cys Met Gln Ala Leu Gln Thr
 85 90 95
 Pro Arg Thr Phe Gly Gln Gly Thr Lys val Glu Ile Lys
 100 105 110

<210> 7
 <211> 100
 <212> PRT
 <213> Homo sapiens

<400> 7
 Asp Ile val Met Thr Gln Ser Pro Leu Ser Leu Pro val Thr Pro Gly
 1 5 10 15
 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
 20 25 30
 Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
 35 40 45

SeqListCorrected.txt

Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly val Pro
 50 55 60
 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
 65 70 75 80
 Ser Arg val Glu Ala Glu Asp val Gly val Tyr Tyr Cys Met Gln Ala
 85 90 95
 Leu Gln Thr Pro
 100

<210> 8
 <211> 138
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> humanized 3D6 heavy chain variable region

<221> SIGNAL
 <222> (1)...(19)

<400> 8
 Met Asn Phe Gly Leu Ser Leu Ile Phe Leu val Leu val Leu Lys Gly
 -15 -10 -5
 val Gln Cys Glu val Gln Leu Leu Glu Ser Gly Gly Gly Leu val Gln
 1 5 10
 Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
 15 20 25
 Ser Asn Tyr Gly Met Ser Trp val Arg Gln Ala Pro Gly Lys Gly Leu
 30 35 40 45
 Glu Trp val Ala Ser Ile Arg Ser Gly Gly Arg Thr Tyr Tyr Ser
 50 55 60
 Asp Asn val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn
 65 70 75
 Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu
 80 85 90
 Tyr Tyr Cys val Arg Tyr Asp His Tyr Ser Gly Ser Ser Asp Tyr Trp
 95 100 105
 Gly Gln Gly Thr Leu val Thr val Ser Ser
 110 115

<210> 9
 <211> 121
 <212> PRT
 <213> Homo sapiens

<400> 9
 Glu val Gln Leu Leu Glu Ser Gly Gly Gly Leu val Gln Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30
 Ala val Ser Trp val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp val
 35 40 45
 Ser Ala Ile Ser Gly Ser Gly Ser Thr Tyr Tyr Ala Asp Ser val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys
 85 90 95
 Ala Lys Asp Asn Tyr Asp Phe Trp Ser Gly Thr Phe Asp Tyr Trp Gly
 100 105 110
 Gln Gly Thr Leu val Thr val Ser Ser

Page 5

SeqListCorrected.txt

115

120

<210> 10
 <211> 98
 <212> PRT
 <213> Homo sapiens

<400> 10
 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
 50 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 Ala Lys

<210> 11
 <211> 132
 <212> PRT
 <213> Artificial Sequence

<220>
 <221> SIGNAL
 <222> (1)...(20)

<223> humanized 3q6 light chain variable region

<400> 11
 Met Met Ser Pro Ala Gln Phe Leu Phe Leu Leu Val Leu Trp Ile Arg
 -20 -15 -10 -5
 Glu Thr Asn Gly Asp Val Met Thr Gln Ser Pro Leu Ser Leu Pro
 1 Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser
 15 20 25
 Leu Leu Asp Ser Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Lys
 30 35 40
 Pro Gly Gln Ser Pro Gln Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp
 45 50 55 60
 Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe
 65 70 75
 Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr
 80 85 90
 Cys Trp Gln Gly Thr His Phe Pro Arg Thr Phe Gly Gln Gly Thr Lys
 95 100 105
 Val Glu Ile Lys
 110

<210> 12
 <211> 138
 <212> PRT
 <213> Artificial Sequence

<220>

Page 6

seqlistCorrected.txt

<223> Humanized 3D6 light chain variable region

<221> SIGNAL
<222> (1)...(19)

<400> 12
Met Asn Phe Gly Leu Ser Leu Ile Phe Leu val Leu val Leu Lys Gly
-15 -10 -5
val Gln Cys Glu val Gln Leu Leu Glu Ser Gly Gly Gly Leu val Gln
1 10
Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
15 20 25
Ser Asn Tyr Gly Met Ser Trp val Arg Gln Ala Pro Gly Lys Gly Leu
30 35 40 45
Glu Trp val Ala Ser Ile Arg Ser Gly Gly Gly Arg Thr Tyr Tyr Ser
50 55 60
Asp Asn val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
65 70 75
Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala val
80 85 90
Tyr Tyr Cys val Arg Tyr Asp His Tyr Ser Gly Ser Ser Asp Tyr Trp
95 100 105
Gly Gln Gly Thr Leu val Thr val Ser Ser
110 115

<210> 13
<211> 393
<212> DNA
<213> Mus musculus

<220>
<221> CDS
<222> (1)...(393)

<221> sig_peptide
<222> (1)...(57)

<400> 13
atg aag ttg cct gtt agg ctg ttg gta ctg atg ttc tgg att cct gct 48
Met Lys Leu Pro val Arg Leu Leu val Leu Met Phe Trp Ile Pro Ala -5
-15
tcc agc agt gat gtt ttg atg acc caa act cca ctc tcc ctg cct gtc 96
Ser Ser Ser Asp val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro val 10
1
agt ctt gga gat caa gcc tcc atc tct tgc aga tct agt cag aac att 144
Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Asn Ile 20 25
15
ata cat agt aat gga aac acc tat tta gaa tgg tac ctg cag aaa cca 192
Ile His Ser Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro 30 35 40 45
ggc cag tct cca aag ctg ctg atc tac aaa gtt tcc aac cga ttt tct 240
Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys val Ser Asn Arg Phe Ser 50 55 60
ggg gtc cca gac agg ttc agt ggc agt gga tca ggg aca gat ttc aca 288
Gly val Pro Asp Arg Phe Ser Gly Ser Gly Thr Asp Phe Thr 65 70 75

SeqListCorrected.txt

ctc aag atc aag aaa gtc gag gct gag gat ctg gga att tat tac tgc 336
 Leu Lys Ile Lys Lys Val Glu Ala Glu Asp Leu Gly Ile Tyr Tyr Cys
 80 85 90

ttt caa ggt tca cat gtt ccg ctc acg ttc ggt gct ggg acc aag ctg 384
 Phe Gln Gly Ser His Val Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu
 95 100 105

393

gag ctg gaa
 Glu Leu Glu
 110

<210> 14
 <211> 131
 <212> PRT
 <213> Mus musculus

<220>
 <221> SIGNAL
 <222> (1)...(19)

<400> 14
 Met Lys Leu Pro Val Arg Leu Leu Val Leu Met Phe Trp Ile Pro Ala
 -15 -10 -5
 Ser Ser Ser Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val
 1 5 10
 Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Asn Ile
 15 20 25
 Ile His Ser Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro
 30 35 40 45
 Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser
 50 55 60
 Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
 65 70 75
 Leu Lys Ile Lys Lys Val Glu Ala Glu Asp Leu Gly Ile Tyr Tyr Cys
 80 85 90
 Phe Gln Gly Ser His Val Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu
 95 100 105
 Glu Leu Glu
 110

<210> 15
 <211> 426
 <212> DNA
 <213> Mus musculus

<220>
 <221> CDS
 <222> (1)...(426)

<221> sig_peptide
 <222> (1)...(57)

<400> 15
 atg gac agg ctt act tcc tca ttc ctg ctg ctg att gtc cct gca tat 48
 Met Asp Arg Leu Thr Ser Ser Phe Leu Leu Ile Val Pro Ala Tyr
 -15 -10 -5

gtc ctg tcc cag gct act ctg aaa gag tct ggc cct gga ata ttg cag 96
 val Leu Ser Gln Ala Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Gln
 1 5 10

Page 8

SeqListCorrected.txt

```

tcc tcc cag acc ctc agt ctg acc tgt tct ttc tct ggg ttt tca ctg 144
Ser Ser Gln Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu
15 20 25

agc act tct ggt atg gga gtg agc tgg att cgt cag cct tca gga aag 192
Ser Thr Ser Gly Met Gly Val Ser Trp Ile Arg Gln Pro Ser Gly Lys
30 35 40

ggc ctg gag tgg ctg gca cac att tac tgg gat gat gac aag cgc tat 240
Gly Leu Glu Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr
50 55 60

aac cca tcc ctg aag agc cgg ctc aca atc tcc aag gat acc tcc aga 288
Asn Pro Ser Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Arg
65 70 75

aag cag gra ttc ctc aag atc acc agt gtg gac cct gca gat act gcc 336
Lys Gln Val Phe Leu Lys Ile Thr Ser Val Asp Pro Ala Asp Thr Ala
80 85 90

aca tac tac tgt gtt cga agg ccc att act ccg gra cra gtc gat gct 384
Thr Tyr Tyr Cys Val Arg Arg Pro Ile Thr Pro Val Leu Val Asp Ala
95 100 105

atg gac tac tgg ggt caa gga acc tca gtc acc gtc tcc tca 426
Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser
110 115 120

```

<210> 16
 <211> 142
 <212> PRT
 <213> Mus musculus

<220>
 <221> SIGNAL
 <222> (1)...(19)

```

<400> 16
Met Asp Arg Leu Thr Ser Ser Phe Leu Leu Leu Ile Val Pro Ala Tyr
-15 -10 -5
Val Leu Ser Gln Ala Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Gln
1 10
Ser Ser Gln Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu
15 20 25
Ser Thr Ser Gly Met Gly Val Ser Trp Ile Arg Gln Pro Ser Gly Lys
30 35 40
Gly Leu Glu Trp Leu Ala His Ile Tyr Trp Asp Asp Lys Arg Tyr
50 55 60
Asn Pro Ser Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Arg
65 70 75
Lys Gln Val Phe Leu Lys Ile Thr Ser Val Asp Pro Ala Asp Thr Ala
80 85 90
Thr Tyr Tyr Cys Val Arg Arg Pro Ile Thr Pro Val Leu Val Asp Ala
95 100 105
Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser
110 115 120

```

<210> 17
 <211> 136
 <212> DNA

SeqListCorrected.txt

<213> Artificial Sequence

<220>

<223> primer

<400> 17

tccgcaagct tgcgcacc atggacatgc gcgtgcccgc ccagctgctg ggccctgctga 60
tgctgtgggt gtccggctcc tccggctacg tggatgatgac ccagtcctccc ctgtccctgc 120
ccgtgacccc cggcga 136

<210> 18

<211> 131

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 18

ctgggggggac tggccgggct tctgcagcag ccagttcagg taggtcttgc cgtcggagtc 60
cagcagggac tgggaggact tgcaggagat ggaggcgggc tcgccggggg tcacggggcag 120
ggacaggggg 9 131

<210> 19

<211> 146

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 19

acctgaactg gctgctgcag aagcccggcc agtcccccca gcgcctgac tacctgggtgt 60
ccaagctgga ctccggcgtg cccgaccgct tctccggctc cggctccggc accgacttca 120
ccctgaagat ctcccgctg gaggcc 146

<210> 20

<211> 142

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 20

aattctagga tccactcacg ctgactctcc accttgggtgc cctggccgaa ggtgcggggg 60
aagtgggtgc cctgccagca gtatgacacg cccacgtcct cggcctccac gcgggagatc 120
ttcagggtga agtcgggtcc 99 142

<210> 21

<211> 16

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 21

ctgggggggac tggccg

<210> 22

<211> 22

<212> DNA

16

SeqListCorrected.txt

<<213> Artificial Sequence

<220>

<223> primer

<400> 22

22

acctgaactg gctgctgcag aa

<210> 23

<211> 138

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 23

acagaaagct tgcgcgccact atggagtttg ggctgagctg gctttttctt gtggctattt 60
taagaggtgt ccagtgtgag gtgcagctgc tggagtcagg cggcgacctg gtgcagcccc 120
gcggctcccc gcgcctgt 138

<210> 24

<211> 135

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 24

gccgcgggag cggatggagg ccaccacttc caggcccttg ccggggggcct ggcgcaccca 60
ggacatgccg tagttggaga aggtgaagcc ggaaggcggcg caggacaggc gcaaggagcc 120
gccgggctgc accag 135

<210> 25

<211> 142

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 25

ctggagtggg tggcctcgat ccgctccggc ggcggccgca cctactactc cgacaacgtg 60
aagggccgct tcaccatctc ccgcgacaac gccaaagaact ccctgtacct gcagatgaac 120
tccctgcgcg ccgaggacac cg 142

<210> 26

<211> 144

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 26

ctgcaaggat ccactcaccg gaggacacgg tcaccagggt gccctggccc cagtagtcgg 60
aggagccgga gtagtggtcg tagcgacgc agtagtacag ggcgggtgtcc tcggcgcgca 120
gggagttcat ctgcaggtac aagg 144

<210> 27

<211> 16

<212> DNA

Page 11

seqlistCorrected.txt

<213> Artificial Sequence

<220>

<223> primer

<400> 27

gccgccggag cggatg

16

<210> 28

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 28

ctggagtggg tggcctccat

20

<210> 29

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 29

tccgcaagct tgccgccac

19

<210> 30

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 30

aattctagga tccactcacg ctatgatctc

29

<210> 31

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 31

acagaaagct tgccgccacc atg

23

<210> 32

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 32

ctgcaaggat ccactcaccg ga

22

SeqListCorrected.txt

<210> 33
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> native ABeta peptide

<400> 33
Asp Ala Glu Phe Arg His Asp Ser Gly Tyr
1 5 10

<210> 34
<211> 402
<212> DNA
<213> Artificial Sequence

<220>
<223> h3D6 version 1 VL

<400> 34
atggacatgc gcgtagccgc ccagctgctg ggcctgctga tgcctgagggt gtccggctcc 60
tccggctacg tggtagatgac ccagtcctcc ctgtccctgc ccgtgacccc cggcgagccc 120
gcctccatct cctgcaagtc ctcccagtc ctgctggact ccgacggcaa gacctacctg 180
aactggctgc tgcagaagcc cggccagtc cccagcgcc tgatctacct ggtgtccaag 240
ctggactccg gcgtagccga ccgcttctcc ggcctccggc ccggcaccga cttcaccctg 300
aagatctccc gcgtaggagg cgaggacgtg ggcgtgtact actgctggca gggcaccac 360
ttcccccgca ccttcggcca gggcaccacg gtggagatca ag 402

<210> 35
<211> 402
<212> DNA
<213> Artificial Sequence

<220>
<223> h3D6 version 2 VL

<400> 35
atggacatgc gcgtagccgc ccagctgctg ggcctgctga tgcctgagggt gtccggctcc 60
tccggcgacg tggtagatgac ccagtcctcc ctgtccctgc ccgtgacccc cggcgagccc 120
gcctccatct cctgcaagtc ctcccagtc ctgctggact ccgacggcaa gacctacctg 180
aactggctgc tgcagaagcc cggccagtc cccagcgcc tgatctacct ggtgtccaag 240
ctggactccg gcgtagccga ccgcttctcc ggcctccggc ccggcaccga cttcaccctg 300
aagatctccc gcgtaggagg cgaggacgtg ggcgtgtact actgctggca gggcaccac 360
ttcccccgca ccttcggcca gggcaccacg gtggagatca ag 402

<210> 36
<211> 414
<212> DNA
<213> Artificial Sequence

<220>
<223> h3D6 version 1 VH

<400> 36
atggagtttg ggcagagctg gctttttctt gtggctatct taaaagggtg ccagtgtag 60
gtgcagctgc tggagtcggg cggcggcctg gtgcagcccc gcggctccct gcgcctgtcc 120
tgctcgcct ccggcttcac ctctctccac tacggcatgt cctgggtgag ccaggctccc 180
ggcaaggggc tggagtggtt ggcctccatc cgtccggcg gcggccgac ctactactcc 240
gacacgtga agggccgctt caccatctcc cgcgacaacg ccaagaactc cctgtacctg 300
cagatgaact ccttgccgac cgaggacacc gccctgtact actgctgctg ctacgaccac 360
tactccggct cctccgacta ctggggccag ggcaccctgg tgaccgtgtc ctcc 414

SeqListCorrected.txt

<210> 37
<211> 414
<212> DNA
<213> Artificial Sequence

<220>
<223> h3D6 version 2 VH

<400> 37
atggagtttg ggctgagctg gctttttctt gtggctattt taaaagggtgt ccagtgtgag 60
gtgagctgctc tggagtcctg cggcggcctg gtgcagcccg gcggctccct gcgcctgtcc 120
tgcgctgctt cgggcttcac ctctcccaac tacggcatgt cctgggtgct ccaggccccc 180
ggcaaggggc tggagtggtt ggcctccatc cgtccggcg gcggccgcac ctactactcc 240
gacaacgtga agggccgctt caccatctcc cgcgacaact ccaagaacac cctgtacctg 300
cagatgaact ccttgcgctc cgaggacacc gccgtgtact actgcgtgct ctacgaccac 360
tactccggct cctccgacta ctggggccag ggcacctgtg tgaccgtgtc ctcc 414

<210> 38
<211> 770
<212> PRT
<213> Homo sapiens

<400> 38
Met Leu Pro Gly Leu Ala Leu Leu Leu Ala Ala Trp Thr Ala Arg
1 5 10 15
Ala Leu Glu Val Pro Thr Asp Gly Asn Ala Gly Leu Leu Ala Glu Pro
20 25 30
Gln Ile Ala Met Phe Cys Gly Arg Leu Asn Met His Met Asn Val Gln
35 40 45
Asn Gly Lys Trp Asp Ser Asp Pro Ser Gly Thr Lys Thr Cys Ile Asp
50 55 60
Thr Lys Glu Gly Ile Leu Gln Tyr Cys Gln Glu Val Tyr Pro Glu Leu
65 70 75 80
Gln Ile Thr Asn Val Val Glu Ala Asn Gln Pro Val Thr Ile Gln Asn
85 90 95
Trp Cys Lys Arg Gly Arg Lys Gln Cys Lys Thr His Pro His Phe Val
100 105 110
Ile Pro Tyr Arg Cys Leu Val Gly Glu Phe Val Ser Asp Ala Leu Leu
115 120 125
Val Pro Asp Lys Cys Lys Phe Leu His Gln Glu Arg Met Asp Val Cys
130 135 140
Glu Thr His Leu His Trp His Thr Val Ala Lys Glu Thr Cys Ser Glu
145 150 155 160
Lys Ser Thr Asn Leu His Asp Tyr Gly Met Leu Leu Pro Cys Gly Ile
165 170 175
Asp Lys Phe Arg Gly Val Glu Phe Val Cys Cys Pro Leu Ala Glu Glu
180 185 190
Ser Asp Asn Val Asp Ser Ala Asp Ala Glu Glu Asp Asp Ser Asp Val
195 200 205
Trp Trp Gly Gly Ala Asp Thr Asp Tyr Ala Asp Gly Ser Glu Asp Lys
210 215 220
Val Val Glu Val Ala Glu Glu Glu Glu Val Ala Glu Val Glu Glu Glu
225 230 235 240
Glu Ala Asp Asp Asp Glu Asp Asp Glu Asp Gly Asp Glu Val Glu Glu
245 250 255
Glu Ala Glu Glu Pro Tyr Glu Glu Ala Thr Glu Arg Thr Thr Ser Ile
260 265 270
Ala Thr Thr Thr Thr Thr Thr Thr Glu Ser Val Glu Glu Val Val Arg
275 280 285
Glu Val Cys Ser Glu Gln Ala Glu Thr Gly Pro Cys Arg Ala Met Ile
290 295 300
Ser Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys Ala Pro Phe Phe

Page 14

SeqListCorrected.txt

305					310					315				320
Tyr	Gly	Gly	Cys	Gly	Gly	Asn	Arg	Asn	Asn	Phe	Asp	Thr	Glu	Tyr
				325				330					335	
Cys	Met	Ala	Val	Cys	Gly	Ser	Ala	Met	Ser	Gln	Ser	Leu	Leu	Thr
			340					345					350	
Thr	Gln	Glu	Pro	Leu	Ala	Arg	Asp	Pro	Val	Lys	Leu	Pro	Thr	Ala
		355					360					365		
Ala	Ser	Thr	Pro	Asp	Ala	Val	Asp	Lys	Tyr	Leu	Glu	Thr	Pro	Gly
	370				375						380			
Glu	Asn	Glu	His	Ala	His	Phe	Gln	Lys	Ala	Lys	Glu	Arg	Leu	Glu
385					390					395				400
Lys	His	Arg	Glu	Arg	Met	Ser	Gln	Val	Met	Arg	Glu	Trp	Glu	Glu
			405						410					415
Glu	Arg	Gln	Ala	Lys	Asn	Leu	Pro	Lys	Ala	Asp	Lys	Lys	Ala	Val
			420					425					430	
Gln	His	Phe	Gln	Glu	Lys	Val	Glu	Ser	Leu	Glu	Gln	Glu	Ala	Ala
		435					440					445		
Glu	Arg	Gln	Gln	Leu	Val	Glu	Thr	His	Met	Ala	Arg	Val	Glu	Ala
	450					455					460			Met
Leu	Asn	Asp	Arg	Arg	Arg	Leu	Ala	Leu	Glu	Asn	Tyr	Ile	Thr	Ala
465					470					475				Leu
Gln	Ala	Val	Pro	Pro	Arg	Pro	Arg	His	Val	Phe	Asn	Met	Leu	Lys
			485						490					495
Tyr	Val	Arg	Ala	Glu	Gln	Lys	Asp	Arg	Gln	His	Thr	Leu	Lys	His
			500					505					510	
Glu	His	Val	Arg	Met	Val	Asp	Pro	Lys	Lys	Ala	Ala	Gln	Ile	Arg
		515					520					525		
Gln	Val	Met	Thr	His	Leu	Arg	Val	Ile	Tyr	Glu	Arg	Met	Asn	Gln
	530					535					540			
Leu	Ser	Leu	Leu	Tyr	Asn	Val	Pro	Ala	Val	Ala	Glu	Glu	Ile	Gln
545					550					555				Asp
Glu	Val	Asp	Glu	Leu	Leu	Gln	Lys	Glu	Gln	Asn	Tyr	Ser	Asp	Val
			565						570				575	
Leu	Ala	Asn	Met	Ile	Ser	Glu	Pro	Arg	Ile	Ser	Tyr	Gly	Asn	Ala
			580					585					590	
Leu	Met	Pro	Ser	Leu	Thr	Glu	Thr	Lys	Thr	Thr	Val	Glu	Leu	Pro
		595					600					605		
Val	Asn	Gly	Glu	Phe	Ser	Leu	Asp	Asp	Leu	Gln	Pro	Trp	His	Ser
	610					615					620			Phe
Gly	Ala	Asp	Ser	Val	Pro	Ala	Asn	Thr	Glu	Asn	Glu	Val	Glu	Pro
625					630					635				640
Asp	Ala	Arg	Pro	Ala	Ala	Asp	Arg	Gly	Leu	Thr	Thr	Arg	Pro	Gly
			645						650					655
Gly	Leu	Thr	Asn	Ile	Lys	Thr	Glu	Glu	Ile	Ser	Glu	Val	Lys	Met
			660					665					670	
Ala	Glu	Phe	Arg	His	Asp	Ser	Gly	Tyr	Glu	Val	His	His	Gln	Lys
		675					680				685			
Val	Phe	Phe	Ala	Glu	Asp	Val	Gly	Ser	Asn	Lys	Gly	Ala	Ile	Ile
	690					695					700			Gly
Leu	Met	Val	Gly	Gly	Val	Val	Ile	Ala	Thr	Val	Ile	Val	Ile	Thr
705					710					715				720
Val	Met	Leu	Lys	Lys	Lys	Gln	Tyr	Thr	Ser	Ile	His	His	Gly	Val
			725						730					735
Glu	Val	Asp	Ala	Ala	Val	Thr	Pro	Glu	Glu	Arg	His	Leu	Ser	Lys
		740						745					750	
Gln	Gln	Asn	Gly	Tyr	Glu	Asn	Pro	Thr	Tyr	Lys	Phe	Phe	Glu	Gln
		755					760					765		Met
Gln	Asn													
	770													

<210> 39
<211> 40

SeqListCorrected.txt

```

<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 39
actagtcgac atgaagttgc ctgttaggct gttggcgctg
40

<210> 40
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 40
actagtcgac atggagwcag acacactccc gytatgggt
39

<210> 41
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 41
actagtcgac atgagtgtgc tcactcaggc cctggsgttg
40

<210> 42
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 42
actagtcgac atgaggrccc ctgctcagwt tyttggmwtc ttg
43

<210> 43
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 43
actagtcgac atggatttcw aggtgcagat twtcagcttc
40

<210> 44
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 44
actagtcgac atgaggckcy ytgysagyt yctgrgg
37

```

Page 16

Seq1stCorrected.txt

<210> 45
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 45
actagtcgac atgggcwcca agatggagtc acakwyycwg g 41

<210> 46
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 46
actagtcgac atgtggggay ctkcttycmm tttttcaatt g 41

<210> 47
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 47
actagtcgac atggtttccw cagctcagct ccttg 35

<210> 48
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 48
actagtcgac atgtatatat gtttgttgc tatttct 37

<210> 49
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 49
actagtcgac atggaagccc cagctcagct tctcttcc 38

<210> 50
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

SeqListCorrected.txt

<400> 50
 ggatcccggg tggatgggga gaagatg 27
 <210> 51
 <211> 37
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> primer
 <400> 51
 actagtcgac atgaaatgca gctgggtcat strcttc 37
 <210> 52
 <211> 36
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> primer
 <400> 52
 actagtcgac atgggatgga gctrratcat sytctt 36
 <210> 53
 <211> 37
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> primer
 <400> 53
 actagtcgac atgaagwtgt ggttzaactg ggttttt 37
 <210> 54
 <211> 35
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> primer
 <400> 54
 actagtcgac atgractttg ggytcagctt grttt 35
 <210> 55
 <211> 40
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> primer
 <400> 55
 actagtcgac atggactcca ggctcaattt agttttcttt 40
 <210> 56
 <211> 37
 <212> DNA
 <213> Artificial Sequence

SeqListCorrected.txt

<220>
<223> primer
<400> 56
actagtcgac atggctgtcy tgggcttctt cttctgc 37
<210> 57
<211> 36
<212> DNA
<213> Artificial Sequence
<220>
<223> primer
<400> 57
actagtcgac atgggatgga gckgggtctt tmtctt 36
<210> 58
<211> 33
<212> DNA
<213> Artificial Sequence
<220>
<223> primer
<400> 58
actagtcgac atgagagtgc tgattctttt gtg 33
<210> 59
<211> 40
<212> DNA
<213> Artificial Sequence
<220>
<223> primer
<400> 59
actagtcgac atggmttggg tgtggamctt gctattcctg 40
<210> 60
<211> 37
<212> DNA
<213> Artificial Sequence
<220>
<223> primer
<400> 60
actagtcgac atgggcagac ttacattctc attcctg 37
<210> 61
<211> 38
<212> DNA
<213> Artificial Sequence
<220>
<223> primer
<400> 61
actagtcgac atggatttgg ggctgatttt ttttattg 38
<210> 62

SeqlistCorrected.txt

<211> 37

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 62

actagtcgac atgacgggtg taagtccttc gtacctg

37

<210> 63

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 63

ggatcccggg agtggataga ctgatgg

27

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted by facsimile to the Patent and Trademark Office, Office of Petitions, facsimile no. (571) 273-8300 at Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Dated February 26, 2007

Signature:

(Am. E. Markagouras)

EXHIBIT 11

Docket No.: ELN-002
(PATENT)**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**In re Patent Application of:
Guriq Basi *et al.*

Application No.: 10/010942

Confirmation No.: 5594

Filed: December 6, 2001

Art Unit: 1649

For: HUMANIZED ANTIBODIES THAT
RECOGNIZE BETA AMYLOID PEPTIDE

Examiner: Ballard, Kimberly A.

AFFIDAVIT BY DEBRA J. MILASINCICMS Petition
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I, Debra J. Milasincic, Esq., declare the following:

1. I am presently a Partner at the firm of Lahive & Cockfield LLP.
2. I reviewed and filed on behalf of Applicants the Response to Missing Parts dated July 1, 2002, including the sequence listing and sequence diskette.
3. It is my understanding that according to our firm practice at this time, sequence listings were prepared by our paralegal department using the PatentIn software. The paralegal department would save three copies of the electronic sequence listing in ASCII format to three

Serial No. 10/010,942


ELN-002

separate diskettes: one USPTO copy, one file copy; and one client copy. The sequence diskettes were then delivered by the paralegal department to the responsible attorney.

4. It is also my understanding that prior to mailing a response to the USPTO which included a sequence diskette, it was our firm practice to confirm the content of the diskette.

5. I declare further that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under §1001 of Title XVIII of the United States Code, and that such willful false statements may jeopardize the validity of this Application for Patent or any patent issuing thereon.

Date: February 26, 2007

Signed: 

Debra J. Milasincic

EXHIBIT 12

Office No. ELN402THE "RECEIVED" STAMP OF THE PATENT AND TRADEMARK OFFICE
IMPRINTED HEREON ACKNOWLEDGES THE FILING OF:

Description of Paper² and No.: Transmittal Letter (1 page, in duplicate); Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (2 pages); Transmittal Letter for Diskette Containing Substitute Sequence Listing (1 page); Diskette Containing Computer Readable Form of Substitute Sequence Listing; Paper Copy of Substitute Sequence Listing (pages 1-22); Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (1 page); and this prepaid acknowledgment postcard.

Title: *Humanized Antibodies That Recognize Beta Amyloid Peptide*


Name of Applicants: Gurig Basi, et al

Intf. or Serial No.: 10/010942

Attorneys: AEM/DIN/CEH


Date: September 16, 2002

"With Certificate of First Class Mailing"



NO POSTAGE STAMP NECESSARY
POSTAGE HAS BEEN PREPAID BY

LAHIVE & COCKFIELD, LLP
28 STATE STREET
BOSTON, MA 02109



02109+1784 07




EXHIBIT 13

For 3 1/2" Disk

Pull Tab to Open

AVERY
Disk Mailer

LAHIVE & COCKFIELD, LLP
28 State Street
Boston, MA 02109

SEQUENCE LISTING UNDER 37 CFR 1.825
(CORRECTED SEQUENCE)

Applicants: Basi, Guriq et al.
Serial No.: 10/010,942
Filed: 2001-12-06
For: HUMANIZED ANTIBODIES THAT
RECOGNIZE BETA AMYLOID PEPTIDE
Copy: USPTO
Docket No. ELN-002 Date: Sept. 16, 2002

3 5" Diskette, 1.44 MB IBM-PC, MS-Windows

DISK MAILER

Handle With Care
FIRST CLASS MAIL

SEQUENCE LISTING UNDER 37 CFR 1.825
(CORRECTED SEQUENCE)

Applicants: Basi, Guriq et al.
Serial No.: 10/010,942
Filed: 2001-12-06
For: HUMANIZED ANTIBODIES THAT
RECOGNIZE BETA AMYLOID PEPTIDE
Copy: USPTO
Docket No.: ELN-002 Date: Sept. 16, 2002

3 5" Diskette, 1.44 MB IBM-PC, MS-Windows

Attorney Docket No. ELN-002

1

EXHIBIT 14

SEQUENCE LISTING

<110> Basi, Gariq
Saldanha, Jose
Yednock, Ted

<120> HUMANIZED ANTIBODIES THAT RECOGNIZE
BETA AMYLOID PEPTIDE

<130> ELN-002

<140> US 10/010,942

<141> 2001-12-06

<150> US 60/251,892

<151> 2000-12-06

<160> 63

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 396

<212> DNA

<213> Mus musculus

<220>

<221> CDS

<222> (1)...(396)

<221> sig_peptide

<222> (1)...(60)

<400> 1

atg atg agt cct gcc cag ttc ctg ttt ctg tta gtg ctc tgg att cgg	48
Met Met Ser Pro Ala Gln Phe Leu Phe Leu Leu Val Leu Trp Ile Arg	
-20 -15 -10 -5	
gaa acc aac ggt tat gtt gtg atg acc cag act cca ctc act ttg tgg	96
Glu Thr Asn Gly Tyr Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser	
1 5 10	
gtt acc att gga caa cca gcc tcc atc tct tgc aag tca agt cag agc	144
Val Thr Ile Gly Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser	
15 20 25	
ctc tta gat agt gat gga aag aca tat ttg aat tgg ttg tta cag agg	192
Leu Leu Asp Ser Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg	
30 35 40	
cca gcc cag tct cca aag cgc cta atc tat ctg gtg tct aaa ctg gac	240
Pro Gly Gln Ser Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp	
45 50 55 60	
tct gga gtc cct gac agg ttc act ggc agt gga tca ggg aca gat ttt	288
Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe	
65 70 75	

Attorney Docket No. ELN-007

2

aca ctg aaa atc agc aga ata gag gct gag gat ttg gga ctt tat tat 336
 Thr Leu Lys Ile Ser Arg Ile Glu Ala Glu Asp Leu Gly Leu Tyr Tyr
 80 85 90

tgc tgg caa ggt aca cat ttt cct cgg acg ttc ggt gga ggc acc aag 384
 Cys Trp Gln Gly Thr His Phe Pro Arg Thr Phe Gly Gly Gly Thr Lys
 95 100 105

ctg gaa atc aaa 396
 Leu Glu Ile Lys
 110

<210> 2
 <211> 132
 <212> PRT
 <213> Mus musculus

<220>
 <221> SIGNAL
 <222> (1)...(20)

<400> 2
 Met Met Ser Pro Ala Gln Phe Leu Phe Leu Leu Val Leu Trp Ile Arg
 -20 -15 -10 -5
 Glu Thr Asn Gly Tyr Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser
 1 5 10
 Val Thr Ile Gly Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser
 15 20 25
 Leu Leu Asp Ser Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg
 30 35 40
 Pro Gly Gln Ser Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp
 45 50 55 60
 Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe
 65 70 75
 Thr Leu Lys Ile Ser Arg Ile Glu Ala Glu Asp Leu Gly Leu Tyr Tyr
 80 85 90
 Cys Trp Gln Gly Thr His Phe Pro Arg Thr Phe Gly Gly Gly Thr Lys
 95 100 105
 Leu Glu Ile Lys
 110

<210> 3
 <211> 414
 <212> DNA
 <213> Mus musculus

<220>
 <221> CDS
 <222> (1)...(414)

<221> sig_peptide
 <222> (1)...(57)

<400> 3

Anomey Docker No. ELN-007

3

```

atg aac ttc ggg ctc agc ttg att ttc ctt gtc ctt gtt tta aaa ggt 48
Met Asn Phe Gly Leu Ser Leu Ile Phe Leu Val Leu Val Leu Lys Gly
-15 -10 -5

gtc cag tgt gaa gtg aag ctg gtg gag tct ggg gga ggc tta gtg aag 96
Val Gln Cys Glu Val Lys Leu Val Glu Ser Gly Gly Leu Val Lys
1 5 10

cct gga gcg tct ctg aaa ctc tcc tgt gca gcc tct gga ttc act ttc 144
Pro Gly Ala Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
15 20 25

agt aac tat ggc atg tct tgg gtt cgc cag aat tca gac aag agg ctg 192
Ser Asn Tyr Gly Met Ser Trp Val Arg Gln Asn Ser Asp Lys Arg Leu
30 35 40 45

gag tgg gtt gca tcc att agg agt ggt ggt ggt aga acc tac tat tca 240
Glu Trp Val Ala Ser Ile Arg Ser Gly Gly Gly Arg Thr Tyr Tyr Ser
50 55 60

gac aat gta aag ggc cga ttc acc atc tcc aga gag aat gcc aag aac 288
Asp Asn Val Lys Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn
65 70 75

acc ctg tac ctg caa atg agt agt ctg aag tct gag gac acg gcc ttg 336
Thr Leu Tyr Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Leu
80 85 90

tat tat tgt gtc aga tat gat cac tat agt ggt agc tcc gac tac tgg 384
Tyr Tyr Cys Val Arg Tyr Asp His Tyr Ser Gly Ser Ser Asp Tyr Trp
95 100 105

ggc cag ggc acc act gtc aca gtc tcc tca 414
Gly Gln Gly Thr Thr Val Thr Val Ser Ser
110 115

```

<210> 4
 <211> 138
 <212> PRT
 <213> Mus musculus

<220>
 <221> SIGNAL
 <222> (1)...(19)

```

<400> 4
Met Asn Phe Gly Leu Ser Leu Ile Phe Leu Val Leu Val Leu Lys Gly
-15 -10 -5
Val Gln Cys Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys
1 5 10
Pro Gly Ala Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
15 20 25
Ser Asn Tyr Gly Met Ser Trp Val Arg Gln Asn Ser Asp Lys Arg Leu
30 35 40 45
Glu Trp Val Ala Ser Ile Arg Ser Gly Gly Gly Arg Thr Tyr Tyr Ser
50 55 60

```

Attorney Docket No. ELN-002⁷

4

Asp Asn Val Lys Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn
 65 70 75
 Thr Leu Tyr Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Leu
 80 85 90
 Tyr Tyr Cys Val Arg Tyr Asp His Tyr Ser Gly Ser Ser Asp Tyr Trp
 95 100 105
 Gly Gln Gly Thr Thr Val Thr Val Ser Ser
 110 115

<210> 5
 <211> 132
 <212> PRT
 <213> Artificial Sequence

<220>
 <221> SIGNAL
 <222> (1)...(20)

<223> humanized 3D6 light chain variable region

<400> 5
 Met Met Ser Pro Ala Gln Phe Leu Phe Leu Leu Val Leu Trp Ile Arg
 -20 -15 -10 -5
 Glu Thr Asn Gly Tyr Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro
 1 5 10
 Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser
 15 20 25
 Leu Leu Asp Ser Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Lys
 30 35 40
 Pro Gly Gln Ser Pro Gln Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp
 45 50 55 60
 Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe
 65 70 75
 Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr
 80 85 90
 Cys Trp Gln Gly Thr His Phe Pro Arg Thr Phe Gly Gln Gly Thr Lys
 95 100 105
 Val Glu Ile Lys
 110

<210> 6
 <211> 125
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SIGNAL
 <222> (1)...(13)

<400> 6
 Met Gly Leu Leu Met Leu Trp Val Ser Gly Ser Ser Gly Asp Ile Val
 -10 -5 1
 Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala
 5 10 15
 Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr

Attorney Docket No. ELN-004

5

```

20      25      30      35
Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu
40
Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe
55
Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val
70      75      80
Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr
85      90      95
Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100      105      110

```

<210> 7
 <211> 100
 <212> PRT
 <213> Homo sapiens

```

<400> 7
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1      5      10      15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
20      25      30
Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35      40      45
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
50      55      60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65      70      75      80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
85      90      95
Leu Gln Thr Pro
100

```

<210> 8
 <211> 138
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Humanized 3D6 heavy chain variable region
 <221> SIGNAL
 <222> (1)...(19)

```

<400> 8
Met Asn Phe Gly Leu Ser Leu Ile Phe Leu Val Leu Val Leu Lys Gly
-15      -10      -5
Val Gln Cys Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln
1      5      10
Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
15      20      25
Ser Asn Tyr Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
30      35      40      45
Glu Trp Val Ala Ser Ile Arg Ser Gly Gly Gly Arg Thr Tyr Tyr Ser
50      55      60
Asp Asn Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn

```

Attorney Docket No. ELN-002

6

65 70 75
 Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu
 80 85 90
 Tyr Tyr Cys Val Arg Tyr Asp His Tyr Ser Gly Ser Ser Asp Tyr Trp
 95 100 105
 Gly Gln Gly Thr Leu Val Thr Val Ser Ser
 110 115

<210> 9
 <211> 121
 <212> PRT
 <213> Homo sapiens

<400> 9
 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30
 Ala Val Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys
 85 90 95
 Ala Lys Asp Asn Tyr Asp Phe Trp Ser Gly Thr Phe Asp Tyr Trp Gly
 100 105 110
 Gln Gly Thr Leu Val Thr Val Ser Ser
 115 120

<210> 10
 <211> 98
 <212> PRT
 <213> Homo sapiens

<400> 10
 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30
 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Lys

<210> 11
 <211> 132

Attorney Docket No. ELN-007

7

<212> PRT

<213> Artificial Sequence

<220>

<221> SIGNAL

<222> (1)...(20)

<223> humanized 3D6 light chain variable region

<400> 11

```

Met Met Ser Pro Ala Gln Phe Leu Phe Leu Leu Val Leu Trp Ile Arg
-20          -15          -10          -5
Glu Thr Asn Gly Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro
          1          5          10
Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser
          15          20          25
Leu Leu Asp Ser Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Lys
          30          35          40
Pro Gly Gln Ser Pro Gln Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp
45          50          55          60
Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe
          65          70          75
Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr
          80          85          90
Cys Trp Gln Gly Thr His Phe Pro Arg Thr Phe Gly Gln Gly Thr Lys
          95          100          105
Val Glu Ile Lys
          110

```

<210> 12

<211> 138

<212> PRT

<213> Artificial Sequence

<220>

<223> Humanized 3D6 light chain variable region

<221> SIGNAL

<222> (1)...(19)

<400> 12

```

Met Asn Phe Gly Leu Ser Leu Ile Phe Leu Val Leu Val Leu Lys Gly
          -15          -10          -5
Val Gln Cys Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln
          1          5          10
Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
          15          20          25
Ser Asn Tyr Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
30          35          40          45
Glu Trp Val Ala Ser Ile Arg Ser Gly Gly Gly Arg Thr Tyr Tyr Ser
          50          55          60
Asp Asn Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
          65          70          75
Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
          80          85          90
Tyr Tyr Cys Val Arg Tyr Asp His Tyr Ser Gly Ser Ser Asp Tyr Trp

```

Attorney Docket No. ELN-007

8

95 100 105
 Gly Gln Gly Thr Leu Val Thr Val Ser Ser
 110 115

<210> 13
 <211> 393
 <212> DNA
 <213> Mus musculus

<220>
 <221> CDS
 <222> (1)...(393)

<221> sig_peptide
 <222> (1)...(57)

<400> 13
 atg aag ttg cct gtt agg ctg ttg gta ctg atg ttc tgg att cct gct 48
 Met Lys Leu Pro Val Arg Leu Leu Val Leu Met Phe Trp Ile Pro Ala
 -15 -10 -5

tcc agc agt gat gtt ttg atg acc caa act cca ctc tcc ctg cct gtc 96
 Ser Ser Ser Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val
 1 5 10

agt ctt gga gat caa gcc tcc atc tct tgc aga tct agt cag aac att 144
 Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Asn Ile
 15 20 25

ata cat agt aat gga aac acc tat tta gaa tgg tac ctg cag aaa cca 192
 Ile His Ser Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro
 30 35 40 45

ggc cag tct cca aag ctc ctg atc tac aaa gtt tcc aac cga ttt tct 240
 Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser
 50 55 60

ggg gtc cca gac agg ttc agt ggc agt gga tca ggg aca gat ttc aca 288
 Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
 65 70 75

ctc aag atc aag aaa gtg gag gct gag gat ctg gga att tat tac tgc 336
 Leu Lys Ile Lys Lys Val Glu Ala Glu Asp Leu Gly Ile Tyr Tyr Cys
 80 85 90

ttt caa ggt tca cat gtt ccg ctc acg ttc ggt gct ggg acc aag ctg 384
 Phe Gln Gly Ser His Val Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu
 95 100 105

gag ctg gaa 393
 Glu Leu Glu
 110

<210> 14
 <211> 131

Amoney Docket No. ELN-002

9

<212> PRT

<213> Mus musculus

<220>

<221> SIGNAL

<222> (1)...(19)

<400> 14

```

Met Lys Leu Pro Val Arg Leu Leu Val Leu Met Phe Trp Ile Pro Ala
      -15                      -10          -5
Ser Ser Ser Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val
      1                      5              10
Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Asn Ile
      15                      20          25
Ile His Ser Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro
      30                      35          40          45
Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser
      50                      55          60
Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
      65                      70          75
Leu Lys Ile Lys Lys Val Glu Ala Glu Asp Leu Gly Ile Tyr Tyr Cys
      80                      85          90
Phe Gln Gly Ser His Val Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu
      95                      100         105
Glu Leu Glu
110

```

<210> 15

<211> 426

<212> DNA

<213> Mus musculus

<220>

<221> CDS

<222> (1)...(426)

<221> sig_peptide

<222> (1)...(57)

<400> 15

```

atg gac agg ctt act tcc tca ttc ctg ctg ctg att gtc cct gca tat      48
Met Asp Arg Leu Thr Ser Ser Phe Leu Leu Leu Ile Val Pro Ala Tyr
      -15                      -10          -5

gtc ctg tcc cag gct act ctg aaa gag tct ggc cct gga ata ttg cag      96
Val Leu Ser Gln Ala Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Gln
      1                      5              10

tcc tcc cag acc ctc agt ctg act tgt tct ttc tct ggg ttt tca ctg      144
Ser Ser Gln Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu
      15                      20          25

agc act tct ggt atg gga gtg agc tgg att cgt cag cct tca gga aag      192
Ser Thr Ser Gly Met Gly Val Ser Trp Ile Arg Gln Pro Ser Gly Lys
      30                      35          40          45

```

Attorney Docker No. ELN-002-;

10

```

ggg ctg gag tgg ctg gca cac att tac tgg gat gat gac aag cgc tat 240
Gly Leu Glu Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr
                    50                    55                    60

aac cca tcc ctg aag agc cgg ctc aca atc tcc aag gat acc tpc aga 288
Asn Pro Ser Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Arg
                    65                    70                    75

aag cag gta ttc ctc aag atc acc agt gtg gac cct gca gat act gcc 336
Lys Gln Val Phe Leu Lys Ile Thr Ser Val Asp Pro Ala Asp Thr Ala
                    80                    85                    90

aca tac tac tgt gtt cga agg ccc att act ccg gta cta gtc gat gct 384
Thr Tyr Tyr Cys Val Arg Arg Pro Ile Thr Pro Val Leu Val Asp Ala
                    95                    100                    105

atg gac tac tgg ggt caa gga acc tca gtc acc gtc tcc tca 426
Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser
110                    115                    120

```

<210> 16
 <211> 142
 <212> PRT
 <213> Mus musculus

<220>
 <221> SIGNAL
 <222> (1)...(19)

```

<400> 16
Met Asp Arg Leu Thr Ser Ser Phe Leu Leu Leu Ile Val Pro Ala Tyr
                    -15                    -10                    -5
Val Leu Ser Gln Ala Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Gln
                    1                    5                    10
Ser Ser Gln Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu
                    15                    20                    25
Ser Thr Ser Gly Met Gly Val Ser Trp Ile Arg Gln Pro Ser Gly Lys
30                    35                    40                    45
Gly Leu Glu Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr
                    50                    55                    60
Asn Pro Ser Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Arg
                    65                    70                    75
Lys Gln Val Phe Leu Lys Ile Thr Ser Val Asp Pro Ala Asp Thr Ala
                    80                    85                    90
Thr Tyr Tyr Cys Val Arg Arg Pro Ile Thr Pro Val Leu Val Asp Ala
                    95                    100                    105
Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser
110                    115                    120

```

<210> 17
 <211> 136
 <212> DNA
 <213> Artificial Sequence

<220>

Attorney Docket No. ELN-002

11

<223> primer

<400> 17

```
tccgcaagct tgcgcgcacc atggacatgc gcgtgcccgc ccagctgctg ggccctgctga 60
tgcctgtgggt gtccggctcc tccggctacg tggatgatgac ccagtcctcc ctgctccctgc 120
ccgtgacccc cggcga 136
```

<210> 18

<211> 131

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 18

```
ctgggggggac tggccggggt tctgcagcag ccagttcagg taggtcttgc cgtcggagtc 60
cagcaggggac tgggaggact tgcaggagat ggaggcgggc tcgccggggg tcacggggcag 120
ggacagggggg g 131
```

<210> 19

<211> 146

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 19

```
acctgaactg gctgctgcag aagcccgggc agtcccccca gcgcctgac tacctgggtgt 60
ccaagctgga ctccggcgtg cccgaccgt tctccggctc cggctccggc accgacttca 120
ccctgaagat ctcccgctg gaggcc 146
```

<210> 20

<211> 142

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 20

```
aattctagga tccactcacg ctgatctcc accttgggtgc cctggccgaa ggtgcggggg 60
aagtgggtgc cctgccagca gtagtacag cccacgtcct cggcctccac gcgggagatc 120
ttcagggtga agtcgggtgcc gg 142
```

<210> 21

<211> 16

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 21

ctgggggggac tggccg

16

Attorney Docket No. ELN-002

12

<210> 22
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 22
acctgaactg gctgctgcag aa

22

<210> 23
<211> 138
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 23
acagaaagct tgcgcgccacc atygagtttg ggctgagctg gctttttctt gtggctatct 60
taaaaggtgt ccagtgtgag gtgcagctgc tggagtccgg cggcggcctg gtgcagcccg 120
gcggtccct gcgcctgt 138

<210> 24
<211> 135
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 24
gccgcgcgag cggatggagg ccaccactc caggcccttg ccgggggctt ggcgaccca 60
ggacatgccg tagttggaga aggtgaagcc ggaggcggcg caggacagge gcaggagacc 120
gccgggctgc accag 135

<210> 25
<211> 142
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 25
ctggagtggg tggcctccat ccgctccggc ggcggccgca cctactactc cgacaacgtg 60
aagggccgct tcaccatctc ccgcgacaac gccagaact cctgtacct gcagatgaac 120
tccctgcgcg ccgaggacac cg 142

<210> 26
<211> 144
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

Attorney Docket No. ELN-002

13

<400> 26
ctgcaaggat ccactcaccg gaggacacgg tcaccagggt gccctggccc cagtagtcgg 60
aggagccgga gtagtggtcg tagcgcacgc agtagtacag ggcggtgtcc tcggcgcgca 120
gggagttcat ctgcaggtac aggg 144

<210> 27
<211> 16
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 27
gccgcgggag cggatg 16

<210> 28
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 28
ctggagtggg tggcctccat 20

<210> 29
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 29
tccgcaagct tgccgccac 19

<210> 30
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 30
aattctagga tccactcacg attgatctc 29

<210> 31
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

Attorney Docket No. ELN-002

14

<400> 31
acagaaagct tgcgcgccacc atg

23

<210> 32
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 32
ctgcaaggat ccaactcaccg ga

22

<210> 33
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> native ABeta peptide

<400> 33
Asp Ala Glu Phe Arg His Asp Ser Gly Tyr
1 5 10

<210> 34
<211> 402
<212> DNA
<213> Artificial Sequence

<220>
<223> h3D6 version 1 VL

<400> 34
atggacatgc gcgtgccgcg ccagctgctg ggcctgctga tgcctgtgggt gtccggctcc 60
tccggctacg tggatgatgac ccagtcctcc ctgtccctgc ccgtgacccc cggcgagccc 120
gcctccatct cctgcaagtc ctcccagtc ctgctggact ccgacggcaa gacctacctg 180
aactggctgc tgcagaagcc cggccagtc cccagcgcc tgatctacct ggtgtccaag 240
ctggactccg gcgtgcccgga ccgcttctcc ggcctccggt ccggcaccga cttcaccctg 300
aagatctccc gcgtggaggg ccgaggacgtg ggcgtgtact actgctggca gggcaccac 360
ttcccccgca ccttcggcca gggcaccacg gtggagatca ag 402

<210> 35
<211> 402
<212> DNA
<213> Artificial Sequence

<220>
<223> h3D6 version 2 VL

<400> 35
atggacatgc gcgtgccgcg ccagctgctg ggcctgctga tgcctgtgggt gtccggctcc 60
tccggcgacg tggatgatgac ccagtcctcc ctgtccctgc ccgtgacccc cggcgagccc 120
gcctccatct cctgcaagtc ctcccagtc ctgctggact ccgacggcaa gacctacctg 180

Attorney Docket No. ELN-002

15

```

aactggctgc tgcagaagcc eggscagtec cccagcgcc tgatctacct ggtgtccaaag 240
ctggactccg gcgtgccga ccgtttctcc ggtccggct ccggcaccga cttcaccctg 300
aagatctccc gcgtggaggc cgaaggacgtg ggcgtgtact actgctggca gggcaccac 360
ttcccccgca ctttcggcca gggcaccaaag gtggagatca ag 402

```

<210> 36

<211> 414

<212> DNA

<213> Artificial Sequence

<220>

<223> h3D6 version 1 VH

<400> 36

```

atggagtttg ggctgagctg gctttttctt gtggtatatt taaaagggtgt ccagtgtgag 60
gtgcagctgc tggagtccgg cggcggcctg gtgcagcccc gcggctccct gcgcctgtcc 120
tgcccgccct ccggtttcac cttctccaac tacggcatgt cctgggtgcg ccaggccccc 180
ggcaaggggc tggagtgggt ggcctccatc cgtccggcg gcggccgcac ctactactcc 240
gacaacgtga agggccgctt caccatctcc cgcgacaacg ccaagaactc cctgtacctg 300
cagatgaact cctgcgcgc cgaaggacacc gccctgtact actgcgtgcg ctacgaccac 360
tactccggtt cctccgacta ctggggccag ggcaccctgg tgaccgtgtc ctcc 414

```

<210> 37

<211> 414

<212> DNA

<213> Artificial Sequence

<220>

<223> h3D6 version 2 VH

<400> 37

```

atggagtttg ggctgagctg gctttttctt gtggtatatt taaaagggtgt ccagtgtgag 60
gtgcagctgc tggagtccgg cggcggcctg gtgcagcccc gcggctccct gcgcctgtcc 120
tgcccgccct ccggtttcac cttctccaac tacggcatgt cctgggtgcg ccaggccccc 180
ggcaaggggc tggagtgggt ggcctccatc cgtccggcg gcggccgcac ctactactcc 240
gacaacgtga agggccgctt caccatctcc cgcgacaact ccaagaacac cctgtacctg 300
cagatgaact cctgcgcgc cgaaggacacc gccctgtact actgcgtgcg ctacgaccac 360
tactccggtt cctccgacta ctggggccag ggcaccctgg tgaccgtgtc ctcc 414

```

<210> 38

<211> 770

<212> PRT

<213> Homo sapiens

<400> 38

```

Met Leu Pro Gly Leu Ala Leu Leu Leu Ala Ala Trp Thr Ala Arg
1          5          10          15
Ala Leu Glu Val Pro Thr Asp Gly Asn Ala Gly Leu Leu Ala Glu Pro
20          25          30
Gln Ile Ala Met Phe Cys Gly Arg Leu Asn Met His Met Asn Val Gln
35          40          45
Asn Gly Lys Trp Asp Ser Asp Pro Ser Gly Thr Lys Thr Cys Ile Asp
50          55          60
Thr Lys Glu Gly Ile Leu Gln Tyr Cys Gln Glu Val Tyr Pro Glu Leu
65          70          75          80
Gln Ile Thr Asn Val Val Glu Ala Asn Gln Pro Val Thr Ile Gln Asn
85          90          95

```

Attorney Docket No. ELN-002

16

Trp Cys Lys Arg Gly Arg Lys Gln Cys Lys Thr His Pro His Phe Val
 100 105 110
 Ile Pro Tyr Arg Cys Leu Val Gly Glu Phe Val Ser Asp Ala Leu Leu
 115 120 125
 Val Pro Asp Lys Cys Lys Phe Leu His Gln Glu Arg Met Asp Val Cys
 130 135 140
 Glu Thr His Leu His Trp His Thr Val Ala Lys Glu Thr Cys Ser Glu
 145 150 155 160
 Lys Ser Thr Asn Leu His Asp Tyr Gly Met Leu Leu Pro Cys Gly Ile
 165 170 175
 Asp Lys Phe Arg Gly Val Glu Phe Val Cys Cys Pro Leu Ala Glu Glu
 180 185 190
 Ser Asp Asn Val Asp Ser Ala Asp Ala Glu Glu Asp Asp Ser Asp Val
 195 200 205
 Trp Trp Gly Gly Ala Asp Thr Asp Tyr Ala Asp Gly Ser Glu Asp Lys
 210 215 220
 Val Val Glu Val Ala Glu Glu Glu Val Ala Glu Val Glu Glu Glu
 225 230 235 240
 Glu Ala Asp Asp Asp Glu Asp Asp Glu Asp Gly Asp Glu Val Glu Glu
 245 250 255
 Glu Ala Glu Glu Pro Tyr Glu Glu Ala Thr Glu Arg Thr Thr Ser Ile
 260 265 270
 Ala Thr Thr Thr Thr Thr Thr Thr Glu Ser Val Glu Glu Val Val Arg
 275 280 285
 Glu Val Cys Ser Glu Gln Ala Glu Thr Gly Pro Cys Arg Ala Met Ile
 290 295 300
 Ser Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys Ala Pro Phe Phe
 305 310 315 320
 Tyr Gly Gly Cys Gly Gly Asn Arg Asn Asn Phe Asp Thr Glu Glu Tyr
 325 330 335
 Cys Met Ala Val Cys Gly Ser Ala Met Ser Gln Ser Leu Leu Lys Thr
 340 345 350
 Thr Gln Glu Pro Leu Ala Arg Asp Pro Val Lys Leu Pro Thr Thr Ala
 355 360 365
 Ala Ser Thr Pro Asp Ala Val Asp Lys Tyr Leu Glu Thr Pro Gly Asp
 370 375 380
 Glu Asn Glu His Ala His Phe Gln Lys Ala Lys Glu Arg Leu Glu Ala
 385 390 395 400
 Lys His Arg Glu Arg Met Ser Gln Val Met Arg Glu Trp Glu Glu Ala
 405 410 415
 Glu Arg Gln Ala Lys Asn Leu Pro Lys Ala Asp Lys Lys Ala Val Ile
 420 425 430
 Gln His Phe Gln Glu Lys Val Glu Ser Leu Glu Gln Glu Ala Ala Asn
 435 440 445
 Glu Arg Gln Gln Leu Val Glu Thr His Met Ala Arg Val Glu Ala Met
 450 455 460
 Leu Asn Asp Arg Arg Arg Leu Ala Leu Glu Asn Tyr Ile Thr Ala Leu
 465 470 475 480
 Gln Ala Val Pro Pro Arg Pro Arg His Val Phe Asn Met Leu Lys Lys
 485 490 495
 Tyr Val Arg Ala Glu Gln Lys Asp Arg Gln His Thr Leu Lys His Phe
 500 505 510
 Glu His Val Arg Met Val Asp Pro Lys Lys Ala Ala Gln Ile Arg Ser
 515 520 525
 Gln Val Met Thr His Leu Arg Val Ile Tyr Glu Arg Met Asn Gln Ser
 530 535 540
 Leu Ser Leu Leu Tyr Asn Val Pro Ala Val Ala Glu Glu Ile Gln Asp

Attorney Docket No. ELN-002

17

545 550 555 560
 Glu Val Asp Glu Leu Leu Gln Lys Glu Gln Asn Tyr Ser Asp Asp Val
 565 570 575
 Leu Ala Asn Met Ile Ser Glu Pro Arg Ile Ser Tyr Gly Asn Asp Ala
 580 585 590
 Leu Met Pro Ser Leu Thr Glu Thr Lys Thr Thr Val Glu Leu Leu Pro
 595 600 605
 Val Asn Gly Glu Phe Ser Leu Asp Asp Leu Gln Pro Trp His Ser Phe
 610 615 620
 Gly Ala Asp Ser Val Pro Ala Asn Thr Glu Asn Glu Val Glu Pro Val
 625 630 635 640
 Asp Ala Arg Pro Ala Ala Asp Arg Gly Leu Thr Thr Arg Pro Gly Ser
 645 650 655
 Gly Leu Thr Asn Ile Lys Thr Glu Glu Ile Ser Glu Val Lys Met Asp
 660 665 670
 Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys Leu
 675 680 685
 Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile Gly
 690 695 700
 Leu Met Val Gly Gly Val Val Ile Ala Thr Val Ile Val Ile Thr Leu
 705 710 715 720
 Val Met Leu Lys Lys Lys Gln Tyr Thr Ser Ile His His Gly Val Val
 725 730 735
 Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg His Leu Ser Lys Met
 740 745 750
 Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys Phe Phe Glu Gln Met
 755 760 765
 Gln Asn
 770

<210> 39
 <211> 40
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> primer

<400> 39
 actagtcgac atgaagttgc ctgttaggct gttgggtgctg

40

<210> 40
 <211> 39
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> primer

<400> 40
 actagtcgac atggagwcag acacactcct gytatgggt

39

<210> 41
 <211> 40
 <212> DNA
 <213> Artificial Sequence

Attorney Docket No. ELN-002

18

<220>

<223> primer

<400> 41

actagtcgac atgagtggtgc tcaatcaggt cctggsgctg

40

<210> 42

<211> 43

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 42

actagtcgac atgagyrccc ctgctcagwc tyttggmwtc ttg

43

<210> 43

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 43

actagtcgac atggatttgc aggtgcagat twtcagcttc

40

<210> 44

<211> 37

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 44

actagtcgac atgaggtkey ytgytsagyt yctgrgg

37

<210> 45

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 45

actagtcgac atgggcwtca agatggagtc acakwyycwg g

41

<210> 46

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

Attorney Docket No. ELN-007

19

<223> primer

<400> 46

actagtcgac atgtggggay ctkcttycmn tttttcaact g

41

<210> 47

<211> 35

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 47

actagtcgac atggtrtccw casctcagtc ccttg

35

<210> 48

<211> 37

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 48

actagtcgac atgtatatat gtttgcctgc tatttct

37

<210> 49

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 49

actagtcgac atggaagccc cagctcagct tctcttcc

38

<210> 50

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 50

ggatcccggg tggatgggtgg gaagatg

27

<210> 51

<211> 37

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

Attorney Docket No. ELN-002

20

<400> 51

actagtcgac atgaaatgca gctgggcat stctctc

37

<210> 52

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 52

actagtcgac atgggatgga gctrtatcat sytctt

36

<210> 53

<211> 37

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 53

actagtcgac atgaagwrgt ggctaaactg ggttttt

37

<210> 54

<211> 35

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 54

actagtcgac atgractttg ggytcagctt grttt

35

<210> 55

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 55

actagtcgac atggactcca ggetcaattt agttttcctt

40

<210> 56

<211> 37

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 56

actagtcgac atggctgtcy trgsgetret ettcctgc

37

Attorney Docket No. ELN-003

21

<210> 57
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 57
actagtcgac atggratgga gckgggtctt tmtctt 36

<210> 58
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 58
actagtcgac atgagagtgc tgattctttt gtg 33

<210> 59
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 59
actagtcgac atggmttggg tgtggamctt gctattcctg 40

<210> 60
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 60
actagtcgac atgggcagac ttacattctc attcctg 37

<210> 61
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 61
actagtcgac atggattttg ggctgatttt ttttattg 38

<210> 62

Attorney Docket No. ELN-002¹²

22

<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 62
actagtcgac atgatggtgt taagtcttct gtacctg

37

<210> 63
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 63
ggatcccggg agtggataga ctgatgg

27

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted by facsimile to the Patent and Trademark Office, Office of Petitions, facsimile no. (571) 273-8300 at Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.


Dated February 26, 2007 Signature  (Amy E. Mandragouras)

EXHIBIT 15

Docket No.: ELN-002
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Guriq Basi *et al.*

Application No.: 10/010942

Confirmation No.: 5594

Filed: December 6, 2001

Art Unit: 1649

For: HUMANIZED ANTIBODIES THAT
RECOGNIZE BETA AMYLOID PEPTIDE

Examiner: Ballard, Kimberly A.

MS Petition
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT

Dear Sir:

I hereby state that I have reviewed the paper copy of the Sequence Listing identified as Exhibit 6, and have reviewed the paper copy of the Sequence Listing identified as Exhibit 14, and further state that the contents of these Sequence Listings are the same.

Dated: February 26, 2007

Respectfully submitted,



By _____
Amy E. Mandragouras
Registration No.: 36,207
LAHIVE & COCKFIELD, LLP
28 State Street
Boston, Massachusetts 02109
(617) 227-7400
(617) 742-4214 (Fax)
Attorney/Agent for Applicant

EXHIBIT 16

Duplicates in View of USPS Mail Delays - OG Date: 15 January 2002

Page 1 of 1

United States Patent and Trademark Office OG Notices: 15 January 2002**Processing of, and Requirements for, the Filing of
Duplicate Applications and Papers in
Patent Applications in view of USPS Mail Delays**

Although mailed correspondence is being received by the United States Patent and Trademark Office (USPTO or Office), many papers that were mailed by first class mail or Express Mail through the United States Postal Service (USPS) in October and November of 2001 have had their delivery delayed. See Mitigation of Delays in Mail Deliveries to the USPTO, which is posted on the USPTO Internet Web site at: <http://www.uspto.gov/september11/mitigationofmaildelays.htm>.

Some of those papers still have not been received by the USPTO. Although the USPS reports (http://www.usps.com/news/2001/press/pr01_1023fact.htm) that "98% of mail at the Brentwood facility has been sanitized and delivered," the USPS has also informed the USPTO that some of the mail that was in the Brentwood Mail facility on October 21 or 22, 2001 may never be received by the USPTO because of anthrax-related decontamination activities. Some applicants, concerned about papers mailed during this time period that have not been received by the USPTO, have filed duplicate copies of the original correspondence along with a statement that meets the requirement in 37 CFR 1.8(b)(3) prior to any holding of abandonment to permit the Office to more timely act on the correspondence. While Office processing of such duplicates will enable the examination process to move forward, applicants should be aware that the submission of duplicate copies may be unnecessary (and could slow down the processing of the application) and that double charging (collection) of the fees may result from subsequent processing by the Office of the delayed original, which may lead to the submission for, and the processing of, refund requests. The Office will try, however, to avoid double charging (collection) of fees as much as is possible.

1. Timeliness of Replies Whose Delivery to the Office has been Delayed:

In accordance with the Office's usual practice, if a paper was mailed with a certificate of mailing, the Office will determine the timeliness (e.g., 35 U.S.C. 133) of the paper based on the certificate of mailing date as set forth in 37 CFR 1.8(a). See Manual of Patent Examining Procedure (MPEP), Eighth Edition, 512, (August 2001). If a paper was sent by Express Mail, the Office will determine the timeliness and filing date of the paper based on the date of deposit with the USPS, which is the "date-in" on the Express Mail mailing label as set forth in 37 CFR 1.10(a). See MPEP 513. Therefore, if the procedures under 37 CFR 1.8 or 1.10 have been followed, any delays in delivery of the paper to the Office will not impact the timeliness of the paper. The Office will process a reply (whose delivery to the Office has been delayed) as timely if the date on the certificate of mailing, or the "date-in" on the Express Mail mailing label, is within the period for reply set forth in the prior Office action or notice.

<http://www.uspto.gov/web/offices/com/sol/cg/2002/week03/paidups.htm>

2/7/2007

Duplicates in View of USPS Mail Delays - OG Date: 15 January 2002

Page 2 of 8

II. Timeliness of Duplicate Replies Filed when the Original has not been Received by the Office:

A. If the duplicate is, itself, timely filed: If applicant submits a duplicate copy of a paper that has not been received in the Office, the duplicate paper will be processed by the Office as timely if the duplicate is filed within the period for reply to the prior Office action or notice (not considering any extensions of time that may have been available).

B. If a duplicate is filed after the expiration of reply period but with acceptable proof of prior timely filing: If the original reply was timely mailed within the period from October 13, 2001 to December 1, 2001 using the certificate of mailing procedure under 37 CFR 1.8, and a duplicate copy is received in the Office after the period for reply has expired, then the Office shall accept the duplicate as the reply, and to have been timely filed, if applicant submits:

(1) a copy of the previously mailed reply and certificate of mailing of the previously mailed reply (the certificate of mailing must be signed and the certificate of mailing must itself indicate the date of mailing); and

(2) a statement that the reply was previously mailed to the USPTO on the date indicated on the certificate of mailing.

It is not sufficient to stamp the reply "Duplicate" or "Copy" and to fax the document to the USPTO, a statement is always required. The statement can be part of the fax transmittal cover sheet or the cover letter so long as the fax transmittal sheet is signed as specified below. The statement must be signed by: the person who personally mailed the original reply, a registered patent attorney or agent, the assignee of the entire interest, or the applicant (all of the inventors or the party qualified under 37 CFR 1.42, 1.43 or 1.47). For example, the statement may be: "This is a copy of correspondence that was mailed to the USPTO on _____ date" or "This is a copy of an amendment that was mailed to the USPTO on the date of the certificate of mailing."

If a certificate of mailing as set forth in 37 CFR 1.8 was not used (or if the certificate of mailing was not signed, or if the certificate of mailing did not include a date), and applicant does not have a post card receipt for the correspondence, the Office cannot accord the duplicate correspondence any date other than the date that the duplicate was actually received in the Office. If the duplicate copy was not itself timely filed, applicant should consider filing a petition to revive under 37 CFR 1.137(a) or (b).

To the extent that this treatment of showings as set forth 37 CFR 1.8(b)(3) is less stringent than the requirements set forth in 37 CFR 1.8(b)(3), the provisions of 37 CFR 1.8(b)(3) are hereby sua sponte waived for replies mailed on or after October 13, 2001 and no later than December 1, 2001.

III. Establishing that a Paper other than a Reply was Mailed to the USPTO

<http://www.uspto.gov/web/offices/com/sol/og/2002/week03/paidups.htm>

2/7/2007

Duplicates in View of USPS Mail Delays - OG Date: 15 January 2002

Page 3 of 1

A paper that is not a reply to an Office action or is not a correspondence that is required to be filed in the USPTO within a set period of time is NOT entitled to the benefit of a certificate of mailing under 37 CFR 1.8(a). The filing date of such a paper is the actual date of receipt in the USPTO, except as provided by 37 CFR 1.10. For example, a preliminary amendment is not a reply to an Office action and, therefore, would not receive the benefit of a certificate of mailing under 37 CFR 1.8(a). On the other hand, an information disclosure statement (IDS) will be considered to have been filed on the "date that it was received in the Office, or an earlier date of mailing if accompanied by a properly executed certificate of mailing." See MPEP 609, page 600-124. An IDS is entitled to the benefit of a certificate of mailing under 37 CFR 1.8(a) since the IDS is a correspondence that is required to be filed in the USPTO within a set period of time. To establish that a paper not entitled to the benefit of a certificate of mailing under 37 CFR 1.8(a) was filed in the USPTO, applicant must have used Express Mail and comply with the provisions of 37 CFR 1.10, or have a post card receipt establishing that the paper was actually received in the USPTO. Other than in these circumstances, the rules do not provide a mechanism for establishing that such a paper was filed in the USPTO.

IV. Office Will Try to Call Before Abandoning Applications Without a Reply:

In most circumstances, before holding an application to be abandoned, staff from the Technology Centers and the Office of Patent Publication will attempt to call applicants to see if a reply has been previously filed. If a reply has been filed, applicant will be requested to fax (or file) a duplicate copy of the prior (original) paper along with a showing as set forth in 37 CFR 1.8(b)(3) in order to avoid the application from being held abandoned.

If applicant files a duplicate with an acceptable showing as set forth in 37 CFR 1.8(b)(3), it will avoid both the Office holding the application as abandoned, and the processing delays associated with the withdrawal of such abandonment.

V. Duplicate Fee Charges (Collections) are Possible When Duplicates are Filed:

When the Office is processing a duplicate before processing the original, the Office shall charge (collect) all fees that are due for the proper processing of the paper, and will not process any papers that are not accompanied by the appropriate fee. Accordingly, applicants should expect that the same fees may inadvertently be charged (collected) when the Office later processes the original paper. The Office will try to avoid this type of double charging (collecting) by checking to see if the fees required to process a delayed original paper were previously charged (collected) and, if previously charged (collected), the Office will not charge (collect) the fees a second time. The Office, however, cannot guarantee that double charging (collecting) will not occur. If the Office processes fees with both the

<http://www.uspto.gov/web/offices/com/sol/og/2002/week03/patdups.htm>

2/7/2007

Duplicates in View of USPS Mail Delays - OG Date: 15 January 2002

Page 4 of 8

duplicate and then the original papers, applicant may request a refund under 37 CFR 1.26. If the application has been allowed, the refund request should be filed after the patent has been issued in order to avoid printing delays. When the original paper corresponding to the duplicate is received, the original paper will be attached to the duplicate in the application file wrapper and will not be listed as a separate contents entry for the application in the Office's records. This procedure will be used notwithstanding the procedure set forth in MPEP 719.01(a).

VI. How to File a Duplicate Reply during Examination or after Allowance:

A. If the Application is in a Technology Center: If applicant desires to file a duplicate copy of a reply to an Office action, with an appropriate showing as set forth in 37 CFR 1.8(b)(3), the duplicate should be faxed to the appropriate Technology Center. The reply facsimile numbers for each Technology Center that should be used are posted on the USPTO Internet web site at: <http://www.uspto.gov/september11/faxnotice.htm>.

B. If the Application has been Allowed: If applicant desires to file a duplicate Issue Fee transmittal (e.g., a duplicate PTOL-85B) in order to pay the issue fee and any publication fee, along with a duplicate copy of other post allowance correspondence that was submitted with the issue fee transmittal, accompanied by an appropriate showing as set forth 37 CFR 1.8(b)(3), the duplicate submission(s) and the showing(s) should be faxed to Box Issue Fee: (703) 746-4000. If an amendment under 37 CFR 1.312 was mailed before payment of the issue fee, and the Office has not yet received the amendment, applicant should include a copy of the amendment (and a statement explaining when the amendment was filed) with the issue fee payment so that the amendment under 37 CFR 1.312 is not treated as having been filed after payment of the issue fee, and therefore not entered (because amendments after payment of the issue fee are no longer permitted).

VII. Filing of Duplicate New Applications and Replies to OIPE:

The USPTO appreciates, that, where warranted, applicants should take advantage of 37 CFR 1.8(b) and 1.10(e), which permits the filing of duplicate copies of prior correspondence in place of lost or missing originals. While applicants should, as a general rule, promptly file a duplicate (of a new application filing or a reply to an OIPE notice) when they become aware that the Office has not received, and may not ever receive, an item of correspondence, the level of urgency usually associated with such action should take into account the fact that the USPTO expects to receive all, or substantially all, of the delayed correspondence. In addition, correspondence will be treated as filed (37 CFR 1.10) or timely (37 CFR 1.8), if applicant originally filed under those provisions regardless of the length of time that the correspondence took to reach the Office. In the event the Office has not received the original by March 1, 2002 applicant then should file a duplicate. The Office will mail a return post card receipt and/or filing receipt or notice, as it usually does, when correspondence is received by the Office so applicant will be informed when delayed

<http://www.uspto.gov/web/offices/com/sol/og/2002/week03/patdups.htm>

2/7/2007

Duplicates in View of USPS Mail Delays - OG Date: 15 January 2002

Page 5 of 8

correspondence has been received.

When the USPTO receives a duplicate submission, it shall consider a showing that a reply was timely mailed as set forth 37 CFR 1.8(b), or a petition for a filing date under 37 CFR 1.10(e), to have been timely filed so long as the showing or petition is filed by May of 2002. To the extent that this standard for timeliness is less stringent than the requirements set forth in 37 CFR 1.8(b)(1), 1.10(e)(1) and 1.181(f), the provisions of 37 CFR 1.8(b)(1), 1.10(e)(1) and 1.181(f) are hereby sua sponte waived for applications and papers mailed on or after October 13, 2001 and no later than December 1, 2001. Where there is a special need, however, applicants should take advantage of the rules and file duplicates without delay. Special needs could include the following: applications and correspondence mailed on or after October 17, and before October 23, 2001 that have not yet been received by the Office, Patent Cooperation Treaty application filings where priority has been claimed, design applications, replies to a Notice of Incomplete Application (filing date not granted) which was mailed under 37 CFR 1.8, and where certified copies of an application will be needed for priority purposes. In all other situations, before filing a duplicate of a prior mailed correspondence pursuant to 37 CFR 1.8(b) and 1.10(e), applicants might want to wait to see if the original is later received.

If correspondence sent via Express Mail was returned to applicant by the USPS, applicants should not file a duplicate, and should instead mail the original correspondence back to the USPTO as described in the notice "Suspension of the 'Express Mail' Service of United States Postal Service for mail addressed to ZIP Codes 202xx through 205xx" that is posted on the USPTO Internet Web site at: <http://www.uspto.gov/september11/uspsmaildisrup.htm>. Applicants who did not file an application using Express Mail may wish to consider filing a duplicate copy of the application via Express Mail, and not including the basic filing fee, or an authorization to charge the basic filing fee to a deposit account. When a duplicate application is submitted, applicant should anticipate that the duplicate (copy) application will be processed as a new application, any fees due will be attempted to be collected (as by either charging a deposit account if an authorization is given, or by mailing a Notice to File Missing Parts, requiring the filing fee(s)), and a filing receipt mailed. If the filing date accorded to the duplicate copy is an earlier filing date than that accorded the application that was previously mailed by first class mail, then applicant should respond to the Notice to File Missing Parts and pay the basic filing fee. If the application that was previously mailed by first class mail is given a filing date before that of the duplicate, applicant need not reply to the Notice to File Missing Parts in the duplicate application, and can just prosecute the original application (thereby allowing the later-filed duplicate application to go abandoned).

When applicant mails a reply to a Notice from OIPE using a certificate of mailing, the reply will be considered to be timely so long as the certificate of mailing was dated before the due date set in the Notice, regardless of the length of time that it took to reach the

<http://www.uspto.gov/web/offices/com/sol/og/2002/week03/patdups.htm>

2/7/2007

Duplicates in View of USPS Mail Delays - OG Date: 15 January 2002

USPTO. If the date of receipt of the correspondence was important, and applicant did not use Express Mail, and the response has not yet been received, applicant may wish to file a duplicate copy of the reply by Express Mail. An example of such a situation would be where a reply to a Notice of Omitted Items included a copy of a missing page of specification and requested a filing date of the date of receipt of the page of specification. The duplicate correspondence mailed to the Office pursuant to the Express Mail provisions of 37 CFR 1.10 will be given a filing date of the "date in" accorded by the USPS. If the duplicate is faxed to OIPE, the correspondence will be given a filing date as of the date of receipt, or if the actual date of receipt is a Saturday, Sunday or Federal Holiday, the next business day (see 37 CFR 1.6(a)(3)).

At the present time applications held in OIPE that are awaiting replies will not be processed as abandoned (if a reply could have been timely made during this period of delayed mail) and, therefore, calls requesting applicants to submit duplicate copies of replies to such notices will not generally be made. Calls to request such papers may be made for design applications.

VIII. Patent Term Adjustment:

Applications filed on or after May 29, 2000 may be eligible for patent term adjustment if issue of the patent has been delayed due to the failure of the Office to meet one of the time periods set forth in 35 U.S.C. 154(b)(1). See 35 U.S.C. 154(b), 37 CFR 1.703(f) provides that the date indicated on any certificate of mailing or transmission under 37 CFR 1.8 is not taken into account in a patent term adjustment calculation. If a reply to any Office action or notice is filed more than three months after the mailing date of the Office action or notice, the period between the date that is three months after the mailing date of the Office action or notice and the date of receipt (37 CFR 1.6) of the reply is considered a failure to engage in reasonable efforts to conclude prosecution, and any patent term adjustment to which the applicant would otherwise be entitled is required to be reduced by this period. See 35 U.S.C. 154(b)(2)(C)(ii) and 37 CFR 1.704(b). 35 U.S.C. 154(b)(3)(C) and 37 CFR 1.705(c), however, provide that an applicant may request reinstatement of all or part of the period of adjustment reduced pursuant to 35 U.S.C. 154(b)(2)(C) and 37 CFR 1.704(b) for failing to reply to an Office action or notice within three months of the date of mailing of the Office action or notice if the applicant provides a showing that, in spite of all due care, the applicant was unable to reply to the Office action or notice within three months of the date of mailing of the Office action or notice, but 35 U.S.C. 154(b)(3)(C) does not permit the Office to grant any request for reinstatement for more than three additional months for each reply beyond three months from the date of mailing of the Office action or notice.

If a reply to an Office action or notice was mailed on or after October 13, 2001 and no later than December 1, 2001 (as shown on a certificate of mailing under 37 CFR 1.8), and the applicant is

<http://www.uspto.gov/web/offices/com/sol/og/2002/week03/patdups.htm>

2/7/2007

Duplicates in View of USPS Mail Delays - OG Date: 15 January 2002

otherwise entitled to patent term adjustment (or additional patent term adjustment) but for the fact that there was a reduction of such patent term adjustment under 35 U.S.C. 154(b)(2)(C)(ii) and 37 CFR 1.704(b) due to the receipt of such reply by the Office more than three business days after the date indicated on the certificate of mailing, the Office will consider the USPS mail situation discussed in this notice to constitute a sufficient showing that, in spite of all due care, the applicant was unable to reply to the Office action or notice within three months of the date of mailing of the Office action or notice. In this situation, the Office will, subject to the conditions set forth below, reinstate a period equal to the period beginning on the date that is four business days after the date indicated on the certificate of mailing on the reply and the date of receipt (37 CFR 1.6) of the reply in the Office up to a maximum of three months.

If an applicant's request for reinstatement of patent term adjustment for the reason set forth above is the sole basis for requesting a change to the patent term adjustment indicated on the notice of allowance, the Office will waive the requirements of 37 CFR 1.705 (including fees) if the applicant submits a request for reinstatement of patent term meeting the following conditions:

(1) The request is submitted no later than the payment of the issue fee but no earlier than the date of mailing of the notice of allowance (unless the paper that was delayed in the mail was the issue fee payment or other paper submitted with or after payment of the issue fee, in which case the request must be submitted as soon as possible but no later than the day before the date of issue of the patent).

(2) The request is transmitted by facsimile to the Office of Petitions at (703)308-6916.

(3) The request includes:

(a) a copy of the part of page with the certificate of mailing under 37 CFR 1.8 and a description of the paper (e.g., amendment, issue fee transmittal, notice of appeal);

(b) the date of receipt in the Office of the paper; and (c) the number of days requested to be reinstated as a result of the USPS mail situation discussed in this notice.

In addition, if applicant has access to the Patent Application Information Retrieval (PAIR) system, a copy of the PAIR contents records with the entry highlighted should also be included.

Applicants are again reminded that to maximize patent term adjustment they may wish to consider filing replies to Office actions: (1) under the "Express Mail" provisions of 37 CFR 1.10; (2) by facsimile; or (3) by hand-delivery. See Changes to Implement Patent Term Adjustment Under Twenty-Year Patent Term, 65 Fed. Reg. 56366, 56376 (Sept. 18, 2000), 1239 Off. Gaz. Pat. Office 14, 22-23 (Oct. 3, 2000) (final rule) (response to comment 10).

IX. Contact Information:

<http://www.uspto.gov/web/offices/com/sol/og/2002/week03/patdups.htm>

2/7/2007

Duplicates in View of USPS Mail Delays - OG Date: 15 January 2002

Page 8 of 8

If you have a question relating to the status of a reply for an application in a Technology Center, please contact the Customer Service Representative of that Technology Center. If you have a question relating to the receipt of a new application or a reply for an application in OIPE, please contact the Customer Service Center in OIPE at (703) 308-1202. If you have a question relating to the receipt of post allowance correspondence, including issue and publication fee payments, please contact the Customer Service Center of the Office of Publications at (703) 305- 8283.

Questions concerning this notice should be directed to Darnell Jayne, Legal Advisor, Office of Patent Legal Administration at (703) 308-6906.

December 20, 2001

ROBERT SPAR for
STEPHEN G. KUNIN
Deputy Commissioner for
Patent Examination Policy

EXHIBIT 17



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

Dear Patent Practitioner,

The USPTO and the patent community have experienced considerable difficulties since mid-October 2001 due to delays in the delivery of mail by the US Postal Service. I want to assure you that the USPTO is making every effort to deal with this situation in ways that avoid any undue burden upon applicants. Over the last few weeks we have seen an increase in the volume of backlogged mail being delivered and we are working very hard to process this mail as quickly as possible. I ask that you bear with us during this challenge and work with us to the extent possible to minimize the impact of these mail delays.

Unfortunately the decontamination process has damaged some of the mail recently delivered to the USPTO. For example, some patent application papers and drawings including photographs have been stuck together and cannot be separated. Some computer discs have been damaged. Some labels have been blackened so that the text on them cannot be read and some papers have been yellowed and are brittle. The amount of damaged mail is small, about 5%, and the senders are being contacted to supply a duplicate when necessary. Additionally, no application is being held abandoned without us first calling the applicant to ensure that a reply has not been delayed in the mail.

I also understand that there has also been some concern from practitioners that outgoing mail from the Office may have been delayed in some instances. Currently, the USPTO is requesting that applicants follow the procedure set forth in Manual of Patent Examining Procedure (MPEP) 710.06 to establish a delay in receipt of mail if they want to request that the period for reply be reset.

Please consult the USPTO Internet web site (<http://www.uspto.gov>) for updated information on Technology Center facsimile numbers, surface mail alternatives, and other announcements concerning mail delays. Some notices related to the mail delays that have been recently posted on the USPTO web site are listed on the attached table. Section 511 of the MPEP will be revised to state that in the event of a postal emergency an announcement will be placed on the USPTO web site. Note also that the entry of a paper into an application file can be confirmed by checking the PAIR system via our Electronic Business Center on our web site.

Questions related to mail difficulties should be directed to the Office of Patent Legal Administration, by telephone at (703) 308-6906. Alternatively, the questions may be sent via e-mail to PatentPractice@uspto.gov.

Thank you for your continued cooperation as we deal with this difficult situation.

January 16, 2002
Date

/s/
NICHOLAS P. GODICI
Commissioner for Patents

Enclosure: Table of Recent Notices

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.